Available via license: CC BY 4.0
Content may be subject to copyright.
International Journal of
Molecular Sciences
Review
Physiopathological Role of Neuroactive Steroids in
the Peripheral Nervous System
Eva Falvo, Silvia Diviccaro, Roberto Cosimo Melcangi * and Silvia Giatti
Dipartimento di Scienze Farmacologiche e Biomolecolari, Universitàdegli Studi di Milano, 20133 Milan, Italy;
eva.falvo@unimi.it (E.F.); silvia.diviccaro@gmail.com (S.D.); silvia.giatti@unimi.it (S.G.)
*Correspondence: roberto.melcangi@unimi.it; Tel.: +39-02-5031-8238
Received: 16 October 2020; Accepted: 24 November 2020; Published: 26 November 2020
Abstract:
Peripheral neuropathy (PN) refers to many conditions involving damage to the peripheral
nervous system (PNS). Usually, PN causes weakness, numbness and pain and is the result of traumatic
injuries, infections, metabolic problems, inherited causes, or exposure to chemicals. Despite the high
prevalence of PN, available treatments are still unsatisfactory. Neuroactive steroids (i.e., steroid hormones
synthesized by peripheral glands as well as steroids directly synthesized in the nervous system)
represent important physiological regulators of PNS functionality. Data obtained so far and here
discussed, indeed show that in several experimental models of PN the levels of neuroactive steroids
are affected by the pathology and that treatment with these molecules is able to exert protective effects
on several PN features, including neuropathic pain. Of note, the observations that neuroactive steroid
levels are sexually dimorphic not only in physiological status but also in PN, associated with the
finding that PN show sex dimorphic manifestations, may suggest the possibility of a sex specific
therapy based on neuroactive steroids.
Keywords:
peripheral neuropathy; pain; diabetes mellitus; physical injury; chemotherapy-induced
peripheral neuropathy; steroidogenesis; progesterone; testosterone; sex difference
1. Introduction
Peripheral neuropathy (PN) is one of the most common disorders affecting the function of one
(i.e., mononeuropathy) or more peripheral nerves (i.e., multi- or polyneuropathy), with a prevalence of
about 2.4% in the general population that reaches 8% with aging [
1
]. This pathological condition may
be either inherited or acquired. Inherited forms of PN are a group of diseases altogether referred to
as Charcot–Marie–Tooth disease, including demyelinating and axonal variants [
2
]. Instead, acquired
peripheral neuropathy may appear during the aging process, in infections, autoimmune disorders
(e.g., AIDS, rheumatoid arthritis, Guillain–Barr
è
syndrome, sarcoidosis, systemic lupus erythematosus),
in systemic or metabolic disorders (e.g., diabetes mellitus, kidney failure, vitamin deficiencies,
alcoholism), after exposure to toxic compounds (e.g., nitrous oxide, mercury, organic solvents)
and during drug treatment (e.g., chemotherapeutics, anti-tuberculosis medication, antiretroviral).
The pathological reaction of peripheral nerves to these various insults results in a degeneration of
the nerve fibers that may occur as axonal damage and/or primary demyelination. The most common
condition is axonal degeneration, that occurs in metabolic deregulation, ischemia, toxin exposure and
inherited disorders [3].
Patients affected by PN may present, in term of form and intensity, very different clinical
manifestations, such as motor insufficiency (weakness and muscle waste), sensory abnormalities
(numbness, pain, hyperalgesia/allodynia and paresthesia), autonomic symptoms (blurred vision,
altered sweating, nausea or vomiting after meal, urinary hesitancy, male impotence, decreased ability
Int. J. Mol. Sci. 2020,21, 9000; doi:10.3390/ijms21239000 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020,21, 9000 2 of 25
to regulate body temperature, orthostatic hypotension) or a combinations of all, often depending on
the particular disorder [3].
Diagnosis of PN involves a neurophysiological examination of muscles and peripheral nerves as
well as patient complete history to determine the possible etiology. However, this remains unknown in
approximately 50% of cases [
4
], especially for most of the axonal neuropathies. In contrast, clinical evidence
of a demyelinating neuropathy increases the possibility of delineating the etiology and starting an
effective treatment with immune-modulatory drugs [4].
A possible strategy to find diagnostic markers as well an effective pharmacological treatment for
PN could be to shift the focus to new biological targets such as those that are involved in relevant
molecular events in the peripheral nervous system (PNS). From this perspective, neuroactive steroids
may represent a promising option. These molecules are able to modulate nervous system functions.
They can originate from peripheral steroidogenic tissues, like gonads and adrenal glands, or from the
nervous system itself, and for this reason they are also called neurosteroids [
5
]. Different studies have
reported that peripheral nerves are able to synthesize and metabolize these molecules and express
their receptors [
6
]. Therefore, as will be here discussed, peripheral nerves are a target for neuroactive
steroid action. Indeed, they are involved in the regulation of different functions of peripheral nerves,
such as myelination and Schwann cell proliferation [7–26].
2. Synthesis, Metabolism, and Receptors of Neuroactive Steroids in the Peripheral Nervous System
PNS is a source of neuroactive steroids, as reported in Figure 1[
5
,
6
,
27
,
28
]. The first step of
neurosteroidogenesis is the formation of pregnenolone (PREG) from cholesterol by the action of
cytochrome P450 side chain cleavage (P450scc). This step requires the transport of cholesterol
from intracellular stores to the inner mitochondrial membrane by the support of a molecular
complex that includes several proteins, such as the translocator protein-18kDa (TSPO) and the
steroidogenic acute regulatory protein. These proteins, together with cytochrome P450scc, are expressed
by Schwann cells and the neuronal compartment in dorsal root ganglia (DRG) [
29
–
31
]. Indeed,
these cells are also able to convert PREG into other neuroactive steroids. For example, they express
steroidogenic enzymes, such as 3
β
-hydroxysteroid dehydrogenase (3
β
-HSD), which converts PREG into
progesterone (PROG), 5
α
-reductase (5
α
-R) and 3
α
- or 3
β
-hydroxysteroid oxidoreductase (3
α
-HSOR or
3
β
-HSOR), converting PROG and testosterone (T) into their 5
α
- and 3
α
- or 3
β
-hydroxy-5
α
-reduced
metabolites [
6
,
32
,
33
]. In particular, PROG is converted into dihydroprogesterone (DHP) and
subsequently into tetrahydroprogesterone (THP), also known as allopregnanolone, or into isopregnanolone
(i.e., the 3
β
isomer of THP). Similarly, T is converted into dihydrotestosterone (DHT) and then into
5
α
-androstane-3
α
,17
β
-diol (3
α
-diol) or 5
α
-androstane-3
β
,17
β
-diol (3
β
-diol) [
32
]. T may be also
metabolized to 17
β
-estradiol by the enzyme aromatase, even if the main pathway for 17
β
-estradiol
synthesis in endocrine tissues is via androstenedione and estrone conversion [
34
]. The functional
presence of these enzymes has been also confirmed by liquid chromatography tandem mass
spectrometry assessment of neuroactive steroid levels in the peripheral nerves (Figure 1). Indeed, levels
of PREG, PROG and its metabolites (i.e., DHP, THP and isopregnanolone), T and its metabolites (i.e.,
DHT, 3
α
-diol and 3
β
-diol) and dehydroepiandrosterone (DHEA), a neuroactive steroid obtained from
PREG by the action of cytochrome P450c17, have been reported in the rat sciatic nerve. Interestingly,
the levels observed in the nervous system do not reflect exactly what is detected in plasma, further
confirming the production and metabolism of these neuroactive steroids in PNS [35–38].
Int. J. Mol. Sci. 2020,21, 9000 3 of 25
Figure 1.
Steroidogenesis in the peripheral nervous system. Schematic representation of steroidogenic
pathways. The arrows and bidirectional arrows indicate the irreversible and reversible reactions,
respectively. The dashed line indicates a non-direct conversion. Steroids in squares represent molecules
assessed by liquid chromatography tandem mass spectrometry in rat sciatic nerve. Further details
are explained in the text. 3
α
-diol: 5
α
-androstane-3
α
,17
β
-diol; 3
α
-HSOR: 3
α
- hydroxysteroid
oxidoreductase; 3
β
-diol: 5
α
-androstane-3
β
,17
β
-diol; 3
β
-HSD: 3
β
-hydroxysteroid dehydrogenase;
3
β
-HSOR: 3
β
-hydroxysteroid oxidoreductase; 5
α
-R: 5
α
-reductase; 17
β
-HSD: 17
β
-hydroxysteroid
dehydrogenase; AR: Androgen receptor; ARO: Aromatase; DHEA: Dehydroepiandrosterone;
DHP: Dihydroprogesterone; DHT: Dihydrotestosterone; ER: estrogen receptor; GABA
A
R:
γ
-amino
butyric acid type A receptor; mPR: membrane progesterone receptor; P450scc: cytochrome P450
side chain cleavage; PR: progesterone receptor; StAR: Steroidogenic Acute Regulatory Protein;
THP: Tetrahydroprogesterone; TSPO: Translocator protein-18kDa.
In addition to be able to synthesize and metabolize neuroactive steroids, peripheral nerves and
Schwann cells also express classical and non-classical steroid receptors; thus, they represent a target for
the actions of neuroactive steroids (Figure 1). Classical steroid receptors, such as PROG (PR), androgen
(AR), estrogen, glucocorticoid and mineralocorticoid receptors, that bind PROG, DHP, T, DHT, DHEA,
estrogens, glucocorticoid and mineralocorticoid, have been detected in neuronal compartment of
PNS (i.e., DRG) and in glia (i.e., Schwann cells) [
6
,
39
–
46
]. In addition, some neuroactive steroid
metabolites such as 3
α
,5
α
-reduced neuroactive steroids, are known to also bind neurotransmitter
receptor channels and/or to modulate their expression. For example, N-methyl-D-aspartate (NMDA),
γ
-amino butyric acid type A and B (GABA
A
receptor, GABA
B
receptor), serotonin type 3 (5-HT
3
)
and
α
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) [
47
–
54
]. In particular, GABA
A
(i.e.,
α
2,
α
3,
β
1,
β
2 and
β
3 subunits) and GABA
B
(i.e., GABA
B1
and GABA
B2
) receptors have been
identified in peripheral nerves and Schwann cells [
15
,
20
,
55
]. Furthermore, the rat sural nerve expresses
AMPA subunits, NMDA receptor 1 subunits, GluR 5, 6 and 7 kainate subunits [
56
,
57
], and Schwann
cells of mammalian peripheral vestibular system express GluR 2, 3 and 4 [
57
,
58
]. Finally, PROG and
its metabolites may also bind the membrane progesterone receptors (mPRs) [
59
,
60
]. All five mPRs
isoforms as well as progesterone receptor membrane component 1 (PGRMC1) have been detected in
Schwann cells [61,62] (Figure 1).
Int. J. Mol. Sci. 2020,21, 9000 4 of 25
3. Physiological Effects of Neuroactive Steroids in the Peripheral Nervous System
One of the best characterized actions of neuroactive steroids in the PNS is the regulation of the
myelin program. Namely, neuroactive steroids exert their physiological actions on the expression
of myelin proteins as well as of transcription factors involved in the regulation of myelination
acting on classical and non-classical steroid receptors. Indeed, PROG and its metabolites modulate the
expression of myelin proteins of the PNS, such as myelin basic protein (MBP), myelin proteolipid protein,
glycoprotein zero (P0) and peripheral myelin protein (PMP22) as well as myelin formation [
6
,
8
,
9
,
20
,
63
,
64
].
In particular, the expression of P0 in the sciatic nerve of adult male rats, as well as that in Schwann cell
culture, is increased by treatment with PROG, DHP or THP. On the contrary, in the case of PMP22,
only THP is effective [
6
,
20
]. Neuroactive metabolites of T exert similar effects on the synthesis of
myelin proteins. Indeed, in adult male rats, orchidectomy decreases the expression of both P0 and
PMP22 in the sciatic nerve, and further treatment with DHT or 3
α
-diol is able to restore the levels of P0
and PMP22, respectively [
14
,
65
]. A very similar effect is also evident in cultures of rat Schwann cells;
treatment with DHT increases levels of P0 mRNA [
14
], while 3
α
-diol increases PMP22 expression [
21
].
The mechanism underlying these different effects seems to be dependent on the myelin proteins
considered. Indeed, it has been observed that the expression of P0 is under the control of classical
steroid receptors, like PR and AR, while a role for non-classical receptors, such as the GABA
A
receptor,
has been hypothesized in the case of PMP22 [
6
]. In particular, the role of PR in regulating P0 expression
has been confirmed by
in vitro
and
in vivo
experiments. For instance, in rat Schwann cell cultures,
mifepristone, an antagonist of PR, is able to block the stimulatory effect exerted by PROG or its reduced
metabolite, DHP. In agreement,
in vivo
treatment with mifepristone from the first day of life reduces in
20 days the expression of P0 in the sciatic nerve of rats [
66
]. In addition, it has been demonstrated that
a coactivator, the steroid receptor coactivator-1 (SRC-1), participates in the effect of DHP on P0 gene
expression. Finally, as demonstrated in an immortalized Schwann cell line (i.e., MSC80 cells), the stable
transfection, in order to over- or down-express SRC-1, produces, after DHP treatment, an increase or
a complete loss of P0 expression, respectively [
67
]. In further support of PR functioning by nuclear
receptor coactivators in PNS, it has been demonstrated that in female Schwann cells, PR is co-expressed
with another member of the p160 family, such as SRC-2 [68].
Similarly, a role for AR in controlling expression of P0 has also been hypothesized. Indeed,
in vivo
chronic treatment with flutamide, an antagonist of this steroid receptor, decreases the synthesis of
P0 in the sciatic nerve of rats [
65
]. Interestingly, inhibition of AR activity influences synthesis of P0
at adult age only. Therefore, altogether these observations suggest that PROG and its metabolites
are important for inducing P0 synthesis during the first steps of the myelination process, while T
and its metabolites subsequently participate in the maintenance of this process. The role of classical
steroid receptors in controlling P0 expression is further supported by the observation that putative
progesterone responsive elements as well as androgen responsive elements have been reported on the
P0 gene [
14
]. This finding further supports the concept that both PROG and androgens may control
P0 expression.
In contrast to what was observed on P0, the regulation of PMP22 expression appears to be under
the control of the GABA
A
receptor. For instance, treatment with a GABA
A
receptor antagonist, such as
bicuculline, completely abolishes the stimulatory effect exerted by THP on PMP22, while treatment
with an agonist, such as muscimol, exerts a stimulatory effect on PMP22, which is comparable to that
exerted by THP [69].
Neuroactive steroids, in addition to regulating the expression of myelin proteins, also have an
action on transcription factors that play an important role in the physiology of Schwann cells and in their
myelinating program. Indeed, it has been shown that in cultures of Schwann cells PROG stimulates
the gene expression of Krox-20, Krox-24, Egr-3 and FosB [
12
,
23
]. In addition, PROG metabolites affect
the synthesis of transcription factors. For instance, Krox-20 is stimulated by treatment with DHP or
THP, while Sox-10 is only stimulated by DHP [16].
Int. J. Mol. Sci. 2020,21, 9000 5 of 25
In addition to the consolidated capability of THP in controlling myelination in PNS, a recent study
has demonstrated that this neuroactive steroid is also important in regulating the development and
maturation of Schwann cells. These effects are mediated mostly by GABA
A
receptor and Src/FAK
(i.e., non-receptor-type tyrosine kinases involved in the regulation of Schwann cells proliferation,
survival and differentiation) signaling cascade activation, causing actin remodeling, migration and
proliferation of Schwann cells [70].
Not only the metabolites, but also PROG itself, affect Schwann cell proliferation. For example,
as demonstrated by
in vitro
experiments, PROG has a stimulatory effect on proliferation of these
peripheral glial cells [
25
,
71
]. A recent study has shown that mPRs also play a potential role in the PNS
physiology, and specifically in Schwann cells. Indeed, activation of mPRs modulates the expression of
the myelin-associated glycoprotein as well as of several Schwann cell differentiation markers; moreover,
it induces morphological changes and increases Schwann cell migration and proliferation [61,62].
Finally, androgens also have an effect on Schwann cell proliferation. For instance, the number of
terminal Schwann cells unsheathing the synaptic junction between muscles and motor nerve endings
decreased after castration and this effect is neutralized by T administration [13].
4. Protective Effects of Neuroactive Steroids in the Peripheral Nervous System
Neuroactive steroids, beside having protective effects in the central nervous system (CNS) [
72
–
86
],
are also effective in PN [
17
,
21
,
22
,
68
,
85
,
87
–
93
]. As mentioned above, neuroactive steroids may influence
many parameters of PNS and, for this reason, the potential effectiveness of these molecules has been
tested in several experimental models of PN. A background for possible protective effects of neuroactive
steroids was also provided by the finding that the levels of neuroactive steroids are affected in many
types of PN [36–38,84,89,94–96].
4.1. Diabetic Peripheral Neuropathy
More than 50% of patients affected by diabetes mellitus show impairment of the PNS. Different types
of abnormalities can be seen, such as mononeuropathy, mononeuritis multiplex, and polyneuropathy.
In particular, this last condition is characterized by structural and functional alteration of the PNS,
such as nerve conduction velocity (NCV) reduction, paranodal demyelination and degeneration of
axons [
97
,
98
]. Diabetic patients as well as experimental models of diabetes, such as streptozotocin
(STZ)-treated rats (i.e., an experimental model of type 1 diabetes), show reduced activity of the
Na
+
,K
+
-ATPase enzyme and altered nociception, due to a decrease in the number of sensitive
fibers [
99
–
107
]. In the same experimental model, the gene expression of P0 and PMP22 has been
demonstrated to be affected by the pathology [
101
,
106
]. Interestingly, infoldings and outfoldings,
representing myelin invaginations and evaginations in peripheral myelinated nerves respectively,
have been observed. Moreover, other morphological alterations, like altered compaction of myelin,
have been reported [
108
]. In particular, diabetes seems to alter phospholipids, fatty acids and
cholesterol content in the myelin of the sciatic nerve, leading to membrane fluidity modification [
109
].
The experimental model of STZ, three months of diabetes, also induces, in the sciatic nerve, a decrease
of neuroactive steroid levels, such as PREG, PROG, T and their metabolites (i.e., DHT, 3
α
-diol and
THP) [
38
]. In addition, a decrease in neuroactive steroid levels associated with a disruption of axonal
transport and alteration of mitochondrial function has been also reported after one month of diabetes
(i.e., short-term diabetes) [110].
As extensively demonstrated, neuroactive steroids show important neuroprotective functions in
STZ-rats. Indeed, PROG and DHP are able to prevent the increase in the number of fibers with myelin
infoldings in the sciatic nerve of STZ-rats [108]. Neuroactive steroids may also influence biochemical
and functional parameters of peripheral nerves. For instance, DHEA prevents vascular and neuronal
dysfunction in the sciatic nerve of diabetic rats [
111
]. In addition, PROG and its metabolites, DHP and
THP, improve the impairment of NCV and the activity of Na
+
, K
+
-ATPase, and restore skin innervation
density and the altered level of PMP22 and P0 [
101
]. An effect of DHP has also been reproduced
Int. J. Mol. Sci. 2020,21, 9000 6 of 25
in an ex vivo model of hyperglycemia. Thus, DRG cultures exposed to high levels of glucose show
reduced immunostaining for MBP and DHP is able to counteract this effect [
89
]. In the experimental
model, alterations of lipid metabolism have also been observed. DHP treatment of STZ-rats was able to
improve lipid content in peripheral myelin membranes, fatty acid desaturation, and sterol regulatory
element binding protein (SREBP)-1c expression, thus promoting alteration of myelin structure [
112
].
Cross-talk between fatty acid biosynthesis and neuroactive steroids is also supported by observations
performed in SREBP-1c knock-out male mice. Indeed, this experimental model shows PN features [
113
]
associated with altered levels of PREG, PROG, T and their reduced metabolites [96].
In addition, T and its metabolites exert neuroprotective effects in diabetic peripheral neuropathy.
Indeed, DHT or 3
α
-diol treatment improves NCV and counteracts the increase of thermal threshold
induced by diabetes, while only DHT treatment improves the activity of Na
+
, K
+
-ATPase and the
expression of P0 in the sciatic nerve. T, DHT and 3
α
-diol also reverse the reduction of intra-epidermal
nerve fiber density induced by diabetes [
106
]. In this experimental model of PN, a neuroprotective
role of the Liver X Receptor (LXR) has been also demonstrated [
114
]. Indeed, activation of LXR with
GW3965 (i.e., a synthetic ligand of LXR), by promoting steroidogenesis, exerts protective effects on
altered thermal nociception, NCV and Na
+
, K
+
-ATPase activity [
114
]. Similarly, TSPO ligands reduce
the severity of diabetic neuropathy. Indeed, it has been demonstrated that treatment with Ro5-4864
(i.e., a ligand of TSPO) increases the low level of neuroactive steroids, such as PREG, PROG and DHT,
assessed in the sciatic nerve of STZ-animals [
115
]. In addition, it prevents the impairment of NCV and
thermal threshold, while also restoring skin innervation density and P0 mRNA levels, and improving
Na
+
, K
+
-ATPase activity [
115
]. Altogether these observations suggest that activation of LXR or TSPO,
by increasing the levels of neuroactive steroids in the sciatic nerve, exerts neuroprotective effects
in diabetic neuropathy and consequently may represent an alternative to the direct treatment with
neuroactive steroids.
4.2. Aging Process
Aging induces significant biochemical and morphological changes in the peripheral nerves.
Indeed, aging is associated with a decrease of PMP22 and P0 synthesis, and atrophy of large myelinated
fibers, while myelin sheaths undergo an increase in thickness and show various irregularities, such as
myelin ballooning, reduplication and remyelination [
7
,
17
]. These alterations are counteracted by
neuroactive steroid treatment. In particular, the low levels of P0 present in aged male rats are
increased by the treatment with PROG or DHP, while those of PMP22 are significantly increased by
THP treatment [7,17].
PROG and its metabolites also have a clear beneficial effect on the number and shape of myelinated
fibers as well as on the frequency of myelin abnormalities [
7
,
17
]. In particular, the most evident effect of
these molecules is the significant increase in the number of myelinated fibers of small caliber (<5
µ
m).
This positive effect on the number of myelinated fibers may reflect an increased remyelination of
small fibers in the sciatic nerve of aged rats. In addition, treatment with PROG, DHP or THP has
also shown an important effect on myelin abnormalities of axons by reducing the frequency and the
proportion of nerve fibers with irregular shapes. These effects seem to be a peculiarity of PROG and its
metabolites since neither T nor DHT or 3
α
-diol are able to influence the morphological parameters
reported above [7,17].
4.3. Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects of
patients undergoing treatment for cancer. Clinically, CIPN shows deficits in sensory, motor, and autonomic
functions. Several classical chemotherapeutics, such as platinum derivatives, vinka alkaloids and taxanes,
are well-established causes of CIPN [116–118].
On the basis of the neuroprotective effects exerted by neuroactive steroids in other experimental
models of PN, their potential effects have also been evaluated in a model of CIPN, such as that induced
Int. J. Mol. Sci. 2020,21, 9000 7 of 25
by docetaxel (i.e., a semisynthetic taxane employed as an antineoplastic agent for the treatment of breast,
ovarian, and non-small cell lung cancer) [
119
]. Results obtained so far have shown that PROG as well
as its metabolite DHP have positive effects against docetaxel-induced neuropathy, improving thermal
threshold, preventing NCV changes and degeneration of skin nerves in the footpad [
119
]. Furthermore,
neuroactive steroid treatment also prevents the changes in gene expression of P0, PMP22 and MBP
induced by docetaxel in the sciatic nerve of male rats [
119
]. Similarly, PROG metabolites (i.e., DHP and
THP) counteract the decrease in the number of intra-epidermal nerve fibers, of NCV and the pain
transmission abnormalities induced by vincristine [120].
4.4. Physical Injury
Peripheral nerves are often exposed to physical damage (i.e., cutting, crushing, entrapment with
nerve compression) and this may induce a kind of PN classifiable according to the severity of nerve
injury. In the case of crush or cut of the nerve, a process known as Wallerian degeneration occurs. Thus,
the part of axon distal to the site of injury degenerates, with fragmentation of myelin and involvement
of Schwann cells and macrophages [121,122].
The protective and regenerative effects of neuroactive steroids have been demonstrated in
experimental models of degeneration occurring after physical injury of peripheral nerves. Indeed,
the gene expression of P0 is increased by neuroactive steroids after nerve transection. In particular,
PROG or DHP treatment significantly increase the low messenger levels of P0 in the distal portion from
the cut of the rat sciatic nerve [
21
]. In addition, the same steroids counteract the alterations observed
after crush-induced degeneration. For example, increased myelin protein expression and restored
activity of the Na
+
, K
+
-ATPase pump, coupled to improved nociception, have been observed in nerve
crushed animals treated with PROG or DHP [
123
]. Important results have been also obtained with
other neuroactive steroids. For instance, T or DHT treatment accelerates regeneration and functional
recovery of nerves in many rodent peripheral nerve injury models (e.g., hamster facial motoneuron,
rat sciatic motoneuron, rat pudendal motoneuron) [
26
,
124
–
127
]. Finally, it has been reported that
DHEA improves axonal regeneration after sciatic nerve transection [
128
], as well as after crush injury
in rats [129].
5. Neuroactive Steroids, Sex and Peripheral Neuropathy
In physiological conditions, neuroactive steroid levels present sex differences, not only as expected
in plasma levels, but also in different brain areas, in the cerebrospinal fluid (CSF), and in peripheral
nerves (e.g., the sciatic nerve). For instance, the levels of PREG are higher in the CSF, cerebral cortex,
hippocampus and cerebellum of male rats, with respect to females, while the same neuroactive steroid
shows elevated levels in the spinal cord and plasma of females in the diestrous phase [
35
]. In addition,
in the sciatic nerve, neuroactive steroid levels showed sex differences (Figure 2). In particular, levels of
PREG, DHP, THP, DHEA and 17
β
-estradiol are higher in the sciatic nerve of females than in the males
while the levels of isopregnanolone, T, DHT and 3α-diol are higher in the male sciatic nerve [35].
Neurosteroidogenesis shows sex-dimorphic features [
130
] and it may be also influenced by
the peripheral sex steroid environment [
131
]. Indeed, in the CNS, gonadectomy alters the levels of
neuroactive steroids depending on the brain areas considered [
131
]. In addition, changes occurring in
the CNS are different to what is observed in the PNS and both do not reflect the changes occurring in
plasma [
131
], supporting the concept of neurosteroidogenesis. In addition, the effects of gonadectomy
depend on sex and on the duration of gonadal hormone deprivation (i.e., long- vs. short-term
castration) [
131
]. For instance, it has been observed that long-term (4 months) gonadectomy induces
an increase of PREG levels in male rat sciatic nerve compared to control values, but this effect is not
observed after short-term (7 days) gonadectomy, where, in contrast, a decrease of the levels of this
neuroactive steroid occurs. Interestingly, the levels of PROG and its metabolite, THP, in rat sciatic
nerve respond to gonadectomy in a sex-dimorphic way. Indeed, only in females the levels of these
neuroactive steroids are decreased by long-term gonadectomy. On the contrary, the levels of DHEA,
Int. J. Mol. Sci. 2020,21, 9000 8 of 25
are increased by long-term, but not by short-term, gonadectomy in male animals, while they are not
affected in females. Further metabolites of DHEA, such as T and DHT, are significantly decreased by
short- and long-term gonadectomy in males but not in females [131].
Figure 2.
Sexual dimorphism of neuroactive steroid levels in peripheral nerves. Neuroactive steroid
levels in rat sciaticnerve show sexual dimorphism. Further details are described in thetext. T: testosterone;
PREG: pregnanolone; 17β-E: 17β-estradiol.
As mentioned above, PROG and its metabolites regulate myelination. Interestingly, the regulation
of the PMP22 and P0 expression is sexually dimorphic. Indeed, PROG and DHP stimulate P0 mRNA
levels in cultures of male but not in female Schwann cells, while THP is only effective in Schwann cells
derived from females. Moreover, PMP22 is stimulated by PROG only in male Schwann cells while
THP is effective only in female Schwann cells [
132
]. Sex dimorphic effects have also been reported in
Schwann cell proliferation. In particular, it has been observed that PROG stimulates Schwann cell
proliferation only in female cultures [25].
Sex differences have been reported in the incidence and/or manifestation of numerous disorders
of PNS. In agreement, the levels of neuroactive steroids also show sex differences under pathological
conditions [
84
,
133
]. For instance, diabetic peripheral neuropathy is more frequent in men than in
women (ratio male/female 2.9) [
134
,
135
] and men develop neuropathy approximately 4 years earlier
than women [
136
]. Moreover, other sex differences are related to motor nerve conduction and atrophy,
which are more common in males. On the contrary, in females, the major symptoms are related
with pain and negative sensory signs [
137
,
138
]. Sex differences have been also reported in nerve
regeneration after sciatic nerve injury in healthy rats as well as in an experimental model of type 2
diabetes, such as Goto-Kakizaki rats [139].
As mentioned above, in the STZ rat model, neuroactive steroid levels observed in peripheral
nerves are affected by the pathology. These alterations are also sex-dimorphic [
38
]. Indeed, long-term
diabetes (i.e., three months after the induction) affects the levels of PREG, T, DHT and 3
α
-diol in
the male rat sciatic nerve, while an alteration of PROG, THP and isopregnanolone levels is observed
in the female sciatic nerve [
38
]. Interestingly, neuroactive steroid levels in the sciatic nerve are also
altered after one month from diabetes induction. In particular, in male STZ rats, a reduction in T
and DHT levels with an increase of THP levels were observed. In female sciatic nerves, the levels
of the neuroactive steroids assessed were unaffected [
110
]. In the same experimental model, it has
been observed that gonadectomy protects female, but not male animals, from diabetic peripheral
neuropathy by increasing the local levels of specific neuroactive steroids, such as DHEA, T and
DHT [
104
]. In agreement, DHEA treatment protects gonadally intact STZ-female, but not male animals,
from diabetic peripheral neuropathy [91].
In experimental short-term diabetes, axonal transport and mitochondrial functions (i.e., the organelle
where the limiting step of steroidogenesis is located) are also affected in a sex dimorphic way [
110
].
Int. J. Mol. Sci. 2020,21, 9000 9 of 25
Indeed, gene expression and axonal protein content of kinesin family members, like KIF1A, KIF5B,
KIF5A and Miosin Va, involved in axonal transport, are only affected in male STZ-rats. Similarly,
the expression of respiratory chain complex IV as well as key regulators of mitochondrial dynamics
(e.g., fission/fusion processes) are affected only in diabetic male rats [110].
Sex-dimorphic alterations of neuroactive steroid levels have been reported also in other
experimental models of PN. Indeed, as demonstrated in the sciatic nerve of male and female PMP22
transgenic rats (i.e., an experimental model of Charcot–Marie–Tooth type 1), the levels of 3
α
-diol
are strongly decreased only in males and those of isopregnanolone only in females [
37
]. In addition,
it has been recently demonstrated that the latencies of potentials, a feature of PN occurring in Gaucher
disease (i.e., a rare lysosomal storage sphingolipidosis caused by mutation in the GBA1 gene) show a
significant association with sex steroids (i.e., T) only in female patients [
140
]. Finally, sex differences
have been also reported in PN associated with antiretroviral therapy, showing a higher incidence in
female patients [141].
6. Neuropathic Pain and Neuroactive Steroids
Neuropathic pain, an important component of PN, is a chronic pain that may arise after an injury
or disease affecting the somatosensory system [
142
] and that is considered a maladaptive response
of the nervous system to damage [
143
]. Etiological factors producing neuropathic pain include
trigeminal neuralgia, postherpetic neuralgia, painful radiculopathies, diabetic polyneuropathies,
central pain produced by stroke or spinal cord injury (SCI). Moreover, traumatic postsurgical and
CIPN also represent common conditions [
142
,
144
]. Patients show common clinical characteristics,
with the presence of both positive and negative symptoms, representing gain and loss of function
of the somatosensory pathway, respectively. Positive phenomena include both ongoing (also called
spontaneous) and evoked pain, while negative phenomena arise as sensory loss [142].
Unfortunately, even if neuropathic pain afflicts 7–10% of the general population worldwide,
the treatment of this condition is still unsatisfactory, with a substantial number of patients having
decreased quality of life with little or no benefit from available treatment [145].
As mentioned above, when the somatosensory system is injured or damaged by a disease,
the painful signals from PNS to the cortex can be altered, resulting in a maladaptive process [
146
].
This maladaptive process may affect both the PNS and CNS, inducing an increased excitability of the
neuronal pain processing circuitry and generating peripheral or central sensitization, symptomatically
expressed as hyperalgesia and allodynia [
147
]. These events involve different mechanisms, such as:
(i) changes in the phenotype of sensory neurons, affecting different molecules and in particular
neuropeptides like calcitonin gene-related peptide and substance P (SP); (ii) imbalance of excitatory and
inhibitory neurotransmission at the spinal cord dorsal horn (DH) level, involving decreased GABA
A
receptor activity and increased NMDA receptor-mediated currents; (iii) an exacerbated neuroimmune
reaction, with glial activation and the production of inflammatory mediators [143,148–150].
As mentioned above, the treatment of neuropathic pain is only partially effective and for this
reason, it is necessary to propose new strategies, such as suppressing symptoms or preventing the
different events leading to maladaptive plasticity.
As extensively demonstrated, neuroactive steroids control important aspects of development,
activity and plasticity of the nervous system [
5
,
84
,
151
–
154
], therefore they appear as interesting
candidates to manage neuropathic pain. Figure 3summarizes the main effects exerted by neuroactive
steroids in managing neuropathic pain, as detailed below.
Int. J. Mol. Sci. 2020,21, 9000 10 of 25
Figure 3.
Analgesic effects of neuroactive steroids in the peripheral nervous system. Analgesic effects
of progesterone, testosterone, THP and 17
β
-estradiol in several neuropathic pain experimental models.
Abbreviations and details are reported in the text.
Among steroidal compounds, glucocorticoids, like dexamethasone and methylprednisolone,
are routinely used to reduced pain, since they are able to inhibit the pro-inflammatory cytokines and to
up-regulate lipocortin (annexin-1) (i.e., a protein that suppresses phospholipase A2, blocking eicosanoid
production, and inhibiting various leucocyte inflammatory events) [
155
]. However, as reported in
experimental models of neuropathic pain, glucocorticoid receptors (GR) are upregulated in the spinal
DH and contribute to hyperalgesia [
156
]. In addition, neuropathic pain is exacerbated by stress
via glucocorticoid and NMDA receptor activation [
157
]. Moreover, in a chronic constriction injury
(CCI) model, glucocorticoid activation in the early phase of pain induction, produced hyperalgesia.
Finally, in the same experimental model, a GR antagonist mediated a slight mechanical hypoalgesia,
mediated by NMDA receptors, rather than acting on inflammatory mediators [
158
]. Thus, concern in
the use of glucocorticoid for pain treatment has been raised, and a possible role for GR in maladaptive
plasticity has been proposed [159].
In addition to glucocorticoids, PROG and its metabolites are also known to reduce pain-related
behaviors in different models of neuropathic pain [101,120,160–167].
As mentioned above, PROG and its metabolites are able to restore biochemical, functional and
morphological parameters after peripheral nerve injury [
21
,
123
]. For example, in the CCI model,
14 days of PROG treatment, starting 12 days after CCI, improves the electrophysiological changes in
motor and sensory conduction velocity, thermal hyperalgesia, and mechanical allodynia produced by
injury [
168
]. Moreover, Coronel and colleagues reported that early PROG administration, when it is
able to block the post-SCI inflammatory cascade, reduces the number of glial fibrillary acidic protein
(GFAP) positive cells and avoids the development of mechanical and thermal allodynia [
162
]. In a
different model, sciatic nerve ligature, the same authors reported that PROG administration protects
from developing mechanical allodynia and promotes a better response to cold stimulation, through a
reduction of spinal cord central pain sensitization mediators (i.e., the NMDA receptor subunit NR1
and the gamma isoform of protein kinase C—PKC) [160,161].
Similarly, THP plays an important role in pain modulation. As mentioned above, this steroid is
a positive allosteric modulator of GABA
A
receptors [
169
] and, indeed, probably by this mechanism,
it reduces thermal and mechanical hyperalgesia after sciatic nerve ligature [170].
Int. J. Mol. Sci. 2020,21, 9000 11 of 25
In experimental models of painful CIPN, PROG, as well as DHP and THP, are able to stop
neuropathic symptoms evoked by antitumoral drugs like oxaliplatin [
163
] or vincristine [
120
]. Recently,
it has been shown that the prophylactic administration (i.e., three injections every 4 days before
and during the chemotherapy cycle) of 17
α
-hydroxyprogesterone caproate, a synthetic derivate of
PROG, is able to prevent allodynia and the mechanical and cold hypersensitivity caused by oxaliplatin.
In addition, the early administration of this steroid prevents chemotherapy-triggered neurotoxicity
and glial activation, suggesting a promising therapeutic strategy [171].
Many studies have also shown an important role of a heterogeneous family of voltage-gated Ca
2+
channels in the development of neuropathic pain [
172
,
173
]. Therefore, the pharmacological modulation
of T-type Ca
2+
channel currents may be of value in the management of this type of pain [
174
,
175
].
Interestingly, it has been reported that an important part of the anti-nociceptive action of THP in
neuropathic pain is due to its ability to block T-type Ca
2+
channels [
176
]. This hypothesis is supported
by the fact that structural modifications of 3
α
,5
α
-reduced neuroactive steroids, which eliminate the
interaction with calcium channels but preserve that on GABA
A
receptors, cause complete loss of
analgesic activity induced by these steroids. These observations suggest that their peripheral analgesic
action is mediated mainly by T-channels and only to a smaller extent by GABA
A
receptors [
176
].
Indeed, administration of a synthetic 3
α
,5
α
-reduced analog of neuroactive steroids, such as
(3
β
,5
α
,17
β
)-17-hydroxyestrane-3-carbonitrile (ECN, i.e., a blocker of T-channels without potentiating
effects on GABA
A
receptors) induces potent analgesia in healthy rats. Interestingly, when this
treatment is combined with a GABA
A
selective neurosteroid without analgesic effect per se, such as
(3
α
,5
α
)-3-hydroxy-13,24-cyclo-18,21-dinorchol-22-en-24-ol (CDNC24), the antinociceptive effects of
ECN are strongly potentiated. This synergistic effect is abrogated by bicuculline, an antagonist of
GABA
A
receptors. Based on these results, a correlation between GABA
A
receptors and T-channels
in peripheral nociceptive signaling has been suggested, and this cooperation might be used in order
to alleviate acute pain [
176
]. In addition, these two synthetic analogs (i.e., ECN and CDNC24)
may also alleviate pain in chronic neuropathy. For instance, in a model of CCI of the sciatic nerve,
local intraplantar injection of either CDNC24 or ECN, is more effective in alleviating thermal nociception
in neuropathic animals than THP [
165
]. This can be explained by the fact that synthetic steroids,
in comparison to THP, are more selective to either GABAAand/or T-channels [165].
As mentioned above, after a lesion or a disease of the nervous system, PROG exerts beneficial
effects while avoiding maladaptive plasticity and pain behaviors. These effects may be mediated by the
capability of PROG to interact with a variety of receptors, such as PR, mPR, and PGRMC1. In addition,
PROG acts as a competitive antagonist of sigma-1 receptor [
52
], expressed in the dorsal spinal cord
and associated with pain and central sensitization [
177
]. On the other hand, the anti-allodynic
and anxiolytic effects of PROG may be also due to its rapid conversion into THP, which reinforces
inhibitory neurotransmission by acting as a positive allosteric modulator of GABA
A
receptors [
169
]
and also enhancing expression of specific receptor subunits [
178
]. In particular, in pain perception,
the correlation among GABA
A
receptors, neuroactive steroids and the PKC isoform epsilon has also
emerged. For instance, it has been proposed that 3
α
,5
α
-reduced neuroactive steroids may take part in a
compensatory mechanism in response to continued activation of the spinal nociceptive system during
pain conditions. In contrast, PKC epsilon prevents further 3
α
,5
α
-metabolite-dependent potentiation,
without decreasing the basal modulatory effect of these neuroactive steroids [
179
,
180
]. Recently,
this concept has been further extended by proposing a mechanism involving THP, brain-derived
neurotrophic factor and its receptor trkB, and PKC epsilon in neuropathic pain [181].
Neuroactive steroids, in order to control pain in the spinal cord, may also be locally synthesized.
Indeed, different studies have demonstrated that the spinal cord DH of rats expresses many key
steroid-synthesizing enzymes [
29
,
182
–
188
]. For example, in a rat experimental model of neuropathic
pain obtained by sciatic nerve ligature, an up-regulation of enzymatic pathways (P450scc and 3
α
-HSOR)
in DH resulted in increased synthesis of THP [170,184,186].
Int. J. Mol. Sci. 2020,21, 9000 12 of 25
THP synthesis may be also regulated by SP, the major nociceptive neuropeptide released by
primary afferents. Indeed, this nociceptive neuropeptide, through THP biosynthesis inhibition in
the spinal cord, may indirectly decrease the spinal inhibitory tone, thus facilitating noxious signal
transmission [189].
The central role of P450scc induction in neuropathic pain has been assessed in a model of
CCI. Sciatic nerve injury, during the induction phase of neuropathic pain (i.e., 0–3 days after CCI),
significantly increases the spinal P450scc expression in astrocytes but not in neurons [
190
]. The early
block of P450scc, through the administration of a P450scc inhibitor, significantly suppresses the
development of neuropathic pain after CCI. The authors of this study proposed that the effect
could be mediated by inactivation of astrocyte serine racemase, the enzyme converting L-serine to
D-serine, which is a co-activator of NMDA receptors. Indeed, the production of D-serine potentiates
NMDA receptor-mediated signaling, contributing to the development of mechanical allodynia
following peripheral injury [
190
]. These observations suggest a possible therapeutic use of P450scc
inhibitors in order to modulate the development of neuropathic pain. P450scc, as well as P450c17,
the enzyme converting PREG into DHEA, plays an important role in the development of neuropathic
pain. Indeed, in the CCI model, the expression of this enzyme is significantly increased in spinal
astrocytes [
191
]. During the induction phase of neuropathic pain in the CCI model, the administration
of ketoconazole, a P450c17 inhibitor, reduces the development of allodynia and thermal hyperalgesia
in the ipsilateral hind paw [
191
]. Based on these data, it has been suggested that the development of
mechanical allodynia is associated with P450c17 activity during the induction phase of neuropathic
pain. In agreement, the intrathecal administration of DHEA produced a rapid pro-nociceptive and a
delayed anti-nociceptive action in the sciatic nerve ligature model. These observations suggest that
DHEA itself induces a rapid pro-nociceptive action while, after its metabolism into androgens, it exerts
analgesic effects. In agreement, intrathecal T administration promotes anti-nociceptive behaviors in
the same experimental model [
183
]. Therefore, another possible therapeutic strategy may rely on the
modulation of the P450c17 enzyme.
Another important component of neurosteroidogenesis, like TSPO, seems to be involved in the
modulation of neuropathic pain. For instance, TSPO expression is upregulated in astrocytes and
microglial cells in spinal cord DH after L5 spinal nerve ligation [
192
]. Intrathecal administration
of a TSPO agonist, such as Ro5-4864, results in decreased neuropathic pain mediated by an
inhibition of activated astrocytes. These results suggest that the inhibition of spinal astrocytes,
involved in neuropathic pain establishment [
193
–
195
], exerts a role in the protective effects of Ro5-4864.
Pretreatment with the steroidogenic inhibitor aminoglutethimide abolishes the anti-nociceptive action
of this TSPO ligand, further confirming that the protective effects observed are due to activation of
neurosteroidogenesis. Indeed, protective effects of TSPO ligands against neuropathic pain linked to
the increase of neurosteroidogenesis have also been reported in a different experimental model of
PN [
115
]. Therefore, novel therapeutic approaches against neuropathic pain could take ligands for
upregulated proteins, such as TSPO, into consideration.
At the base of the pain perception, there is a possible influence of sex. In general, women report
more pain than men and exhibit higher risk for developing chronic pain [
196
,
197
]. In addition,
as demonstrated in cohorts of patients with type 2 [
198
] or type 1 diabetes [
199
,
200
], females show
higher frequency and intensity of neuropathic pain. In agreement, sex differences have also been
reported in experimental models of different PNs. For instance, in a mouse model of paclitaxel-induced
neuropathic pain, cold allodynia is more evident in females than in male mice [
201
]. In an experimental
model of HIV-1-associated neuropathic pain, increased cold sensitivity and mechanical allodynia have
been reported to be higher in female than in male mice [
202
]. Interestingly, ovariectomy produces
neuropathic pain-like behaviors more similar to male mice in comparison to sham females [
202
],
supporting a role for sex steroids in pain perception. After sciatic nerve ligature, male mice report
a gradual decrease of allodynia and a complete recovery, while in female animals, allodynia is still
present after four months of neuropathy induction [203].
Int. J. Mol. Sci. 2020,21, 9000 13 of 25
Several clinical studies show that gonadal steroids have a central role in gender differences in
pain and analgesia. In addition, a possible correlation may exist between alterations in neuroactive
steroid levels, expression of their receptors and the development of chronic pain [
204
,
205
]. Indeed,
while androgens, in particular T levels, are higher in males and exert analgesic effects in human
and experimental models, estrogens show both hyperalgesic and analgesic effects depending on the
experimental conditions [204,206–208].
The role of peripheral sex steroid hormones on endogenous pain control has been assessed in
an experimental model of pain (i.e., formalin injection) comparing the response between intact and
gonadectomized rats [
209
,
210
]. In both acute (i.e., phasic noxious stimuli) and tonic (i.e., continuous
noxious stimuli) nociceptive phases, gonadectomized male rats present more pain than intact male rats
while gonadectomized females exhibited less nociceptive responses than the control group but only in
the inhibitory interphase (i.e., phase related to active inhibitory mechanism rather than an absence of
nociceptive activity) [
209
]. Hormonal supplementation in this experimental model has shown that
17
β
-estradiol and PROG mainly act on the inhibitory mechanism of pain while T plays a protective
role in pain perception [210].
In the paclitaxel CIPN model, it has been shown that female sex steroid hormones (i.e., PROG and
17
β
-estradiol) are involved in modifying pain intensity, by proinflammatory cytokines in the sensory
nerves [
211
]. Promising results have been obtained with 17
β
-estradiol treatment after sciatic nerve
ligature. Indeed, this steroid induces pain attenuation, a functional improvement of the injured limb,
a faster regenerative process of the sciatic nerve as well as a decrease of neuropathy-induced gliosis [
203
].
17
β
-estradiol exerts analgesic effects via ERs expressed in L4-L5 DH neurons. For instance, in a
neuropathic pain model of SCI, 17
β
-estradiol treatment inhibits microglia and astrocyte activation.
In particular, the factors known to be activated in astrocytes and microglia, like JNK, p38MAPK
and ERK, present decreased levels as a consequence of 17
β
-estradiol treatment and, this, in turn,
reduces the expression of pro-inflammatory mediators, such as IL-1
β
, IL-6 and Cox-2 [
212
]. These data
highlight the protective effects of 17
β
-estradiol on neuropathic pain mediated by ER. In addition,
ER-
β
selective agonists, as well as other structural analogues, present anti-allodynic effects in the
spinal nerve ligation [
213
] and CIPN pain models [
214
], supporting the involvement of ER-
β
in the
analgesic effects mediated by 17β-estradiol.
Altogether, these observations support the idea that the fluctuations of sex steroid levels
may significantly influence pain perception and may provide an interesting background for future
investigations aimed to develop effective sex-specific steroid-based strategies against pain.
7. Conclusions
Data here reported support the concept that neuroactive steroids, synthetic ligands acting on their
receptors or inducing their synthesis, may improve PN symptoms, including neuropathic pain and
consequently may represent an interesting possible therapeutic strategy. In addition, based on the
sexual dimorphism of neuroactive steroids as well as of PN here discussed, a gender specific treatment
based on these compounds may be also proposed. Therefore, even if the molecular mechanisms
behind PN need to still be investigated in detail, the pleiotropic effects exerted by neuroactive steroids
represent an interesting therapeutic option that deserves deeper exploration.
Author Contributions:
Conceptualization: R.C.M. and E.F.; Writing—Original Draft Preparation, E.F.;
Writing—Review & Editing, R.C.M. and S.G.; Supervision: R.C.M. and S.G.; Editing and Figure Preparation:
E.F. and S.D. All authors have read and agreed to the published version of the manuscript.
Funding:
This work was supported from MIUR “Progetto Eccellenza”, PON “Ricerca e Innovazione” PerMedNet
-project ARS01_01226; The financial support of PRIN (2017ZFJCS3) to SG is also gratefully acknowledged.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2020,21, 9000 14 of 25
Abbreviations
3α-diol 5α-androstane-3α,17β-diol
3α-HSOR 3α- hydroxysteroid oxidoreductase
3β-diol 5α-androstane-3β,17β-diol
3β-HSD 3β-hydroxysteroid dehydrogenase
3β-HSOR 3β-hydroxysteroid oxidoreductase
5-HT Serotonin
5α-R 5α-reductase
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AR Androgen receptor
ARO Aromatase
CCI Chronic constriction injury
CDNC24 (3α,5α)-3-hydroxy-13,24-cyclo-18,21-dinorchol-22-en-24-ol
CIPN Chemotherapy-induced peripheral neuropathy
CNS Central nervous system
CSF Cerebrospinal fluid
DH Dorsal horn
DHEA Dehydroepiandrosterone
DHP Dihydroprogesterone
DHT Dihydrotestosterone
DRG Dorsal root ganglia
ECN (3β,5α,17β)-17-hydroxyestrane-3-carbonitrile
ER estrogen receptor
GABA γ-amino butyric acid
GFAP glial fibrillary acidic protein
GR glucocorticoid receptor
IL interleukine
LXR Liver X Receptor
MBP Myelin basic protein
mPRs Membrane progesterone receptors
NCV Nerve conduction velocity
NMDA N-metyl-D-aspartate
P0 Glycoprotein zero
P450scc Cytochrome P450 side chain cleavage
PGRMC1 Progesterone receptor membrane component 1
PKC Protein kinase C
PMP22 Peripheral myelin protein
PN Peripheral neuropathy
PNS Peripheral nervous system
PR Progesterone receptor
PREG Pregnenolone
PROG Progesterone
SCI Spinal cord injury
SP Substance P
SRC-1 Steroid receptor coactivator-1
SREBP-1c Sterol regulatory element binding protein
StAR Steroidogenic Acute Regulatory Protein
STZ Streptozotocin
T Testosterone
THP Tetrahydroprogesterone
TSPO Translocator protein-18kDa
References
1. England, J.D.; Asbury, A.K. Peripheral neuropathy. Lancet 2004,363, 2151–2161. [CrossRef]
2.
Cashman, C.R.; Hoke, A. Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci. Lett.
2015,596, 33–50. [CrossRef] [PubMed]
3.
Barrell, K.; Smith, A.G. Peripheral Neuropathy. Med. Clin. N. Am.
2019
,103, 383–397. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020,21, 9000 15 of 25
4.
Imreova, H.; Pura, M. Differential diagnosis of peripheral neuropathy. Cas. Lek. Cesk.
2005
,144, 628–633,
discussion 633-625.
5.
Melcangi, R.C.; Garcia-Segura, L.M.; Mensah-Nyagan, A.G. Neuroactive steroids: State of the art and new
perspectives. Cell. Mol. Life Sci. 2008,65, 777–797. [CrossRef]
6.
Melcangi, R.C.; Cavarretta, I.T.; Ballabio, M.; Leonelli, E.; Schenone, A.; Azcoitia, I.; Miguel Garcia-Segura, L.;
Magnaghi, V. Peripheral nerves: A target for the action of neuroactive steroids. Brain Res. Rev.
2005
,48,
328–338. [CrossRef]
7.
Azcoitia, I.; Leonelli, E.; Magnaghi, V.; Veiga, S.; Garcia-Segura, L.M.; Melcangi, R.C. Progesterone and
its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological
abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiol. Aging
2003
,24, 853–860.
[CrossRef]
8.
Chan, J.R.; Phillips, L.J., II; Glaser, M. Glucocorticoids and progestins signal the initiation and enhance the
rate of myelin formation. Proc. Natl. Acad. Sci. USA 1998,95, 10459–10464. [CrossRef]
9.
Chan, J.R.; Rodriguez-Waitkus, P.M.; Ng, B.K.; Liang, P.; Glaser, M. Progesterone synthesized by Schwann
cells during myelin formation regulates neuronal gene expression. Mol. Biol. Cell
2000
,11, 2283–2295.
[CrossRef]
10.
Desarnaud, F.; Do Thi,A.N.; Brown, A.M.; Lemke,G.; Suter, U.; Baulieu, E.E.; Schumacher, M. Progesterone stimulates
the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells.
J. Neurochem. 1998,71, 1765–1768. [CrossRef]
11.
Desarnaud, F.; Bidichandani, S.; Patel, P.I.; Baulieu, E.E.; Schumacher, M. Glucocorticosteroids stimulate the
activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. Brain Res.
2000,865, 12–16. [CrossRef]
12.
Guennoun, R.; Benmessahel, Y.; Delespierre, B.; Gouezou, M.; Rajkowski, K.M.; Baulieu, E.E.; Schumacher, M.
Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res. Mol. Brain Res.
2001
,90, 75–82.
[CrossRef]
13.
Lubischer, J.L.; Bebinger, D.M. Regulation of terminal Schwann cell number at the adult neuromuscular
junction. J. Neurosci. 1999,19, RC46. [CrossRef] [PubMed]
14.
Magnaghi, V.; Cavarretta, I.; Zucchi, I.; Susani, L.; Rupprecht, R.; Hermann, B.; Martini, L.; Melcangi, R.C.
Po gene expression is modulated by androgens in the sciatic nerve of adult male rats. Brain Res. Mol.
Brain Res. 1999,70, 36–44. [CrossRef]
15.
Magnaghi, V.; Ballabio, M.; Cavarretta, I.T.; Froestl, W.; Lambert, J.J.; Zucchi, I.; Melcangi, R.C. GABAB receptors
in Schwann cells influence proliferation and myelin protein expression. Eur. J. Neurosci.
2004
,19, 2641–2649.
[CrossRef]
16.
Magnaghi, V.; Ballabio, M.; Roglio, I.; Melcangi, R.C. Progesterone derivatives increase expression of Krox-20
and Sox-10 in rat Schwann cells. J. Mol. Neurosci. 2007,31, 149–157.
17.
Melcangi, R.C.; Azcoitia, I.; Ballabio, M.; Cavarretta, I.; Gonzalez, L.C.; Leonelli, E.; Magnaghi, V.; Veiga, S.;
Garcia-Segura, L.M. Neuroactive steroids influence peripheral myelination: A promising opportunity for
preventing or treating age-dependent dysfunctions of peripheral nerves. Prog. Neurobiol.
2003
,71, 57–66.
[CrossRef]
18.
Melcangi, R.C.; Ballabio, M.; Cavarretta, I.; Gonzalez, L.C.; Leonelli, E.; Veiga, S.; Martini, L.; Magnaghi, V.
Effects of neuroactive steroids on myelin of peripheral nervous system. J. Steroid Biochem. Mol. Biol.
2003
,85,
323–327. [CrossRef]
19.
Melcangi, R.C.; Magnaghi, V.; Cavarretta, I.; Martini, L.; Piva, F. Age-induced decrease of glycoprotein Po
and myelin basic protein gene expression in the rat sciatic nerve. Repair by steroid derivatives. Neuroscience
1998,85, 569–578. [CrossRef]
20.
Melcangi, R.C.; Magnaghi, V.; Cavarretta, I.; Zucchi, I.; Bovolin, P.; D’Urso, D.; Martini, L. Progesterone
derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: Possible mechanisms
of action. J. Neurosci. Res. 1999,56, 349–357. [CrossRef]
21.
Melcangi, R.C.; Magnaghi, V.; Galbiati, M.; Ghelarducci, B.; Sebastiani, L.; Martini, L. The action of steroid
hormones on peripheral myelin proteins: A possible new tool for the rebuilding of myelin? J. Neurocytol.
2000,29, 327–339. [CrossRef]
22.
Melcangi, R.C.; Magnaghi, V.; Martini, L. Aging in peripheral nerves: Regulation of myelin protein genes by
steroid hormones. Prog. Neurobiol. 2000,60, 291–308. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 16 of 25
23.
Mercier, G.; Turque, N.; Schumacher, M. Early activation of transcription factor expression in Schwann cells
by progesterone. Brain Res. Mol. Brain Res. 2001,97, 137–148. [CrossRef]
24.
Rodriguez-Waitkus, P.M.; Lafollette, A.J.; Ng, B.K.; Zhu, T.S.; Conrad, H.E.; Glaser, M. Steroid hormone
signaling between Schwann cells and neurons regulates the rate of myelin synthesis. Ann. N. Y. Acad. Sci.
2003,1007, 340–348. [CrossRef] [PubMed]
25.
Fex Svenningsen, A.; Kanje, M. Estrogen and progesterone stimulate Schwann cell proliferation in a sex- and
age-dependent manner. J. Neurosci. Res. 1999,57, 124–130. [CrossRef]
26.
Tanzer, L.; Jones, K.J. Neurotherapeutic action of testosterone on hamster facial nerve regeneration: Temporal
window of effects. Horm. Behav. 2004,45, 339–344. [CrossRef]
27.
Schumacher, M.; Guennoun, R.; Mercier, G.; Desarnaud, F.; Lacor, P.; Benavides, J.; Ferzaz, B.; Robert, F.;
Baulieu, E.E. Progesterone synthesis and myelin formation in peripheral nerves. Brain Res. Rev.
2001
,37,
343–359. [CrossRef]
28.
Schumacher, M.; Weill-Engerer, S.; Liere, P.; Robert, F.; Franklin, R.J.; Garcia-Segura, L.M.; Lambert, J.J.;
Mayo, W.; Melcangi, R.C.; Parducz, A.; et al. Steroid hormones and neurosteroids in normal and pathological
aging of the nervous system. Prog. Neurobiol. 2003,71, 3–29. [CrossRef]
29.
Patte-Mensah, C.; Kappes, V.; Freund-Mercier, M.J.; Tsutsui, K.; Mensah-Nyagan, A.G. Cellular distribution
and bioactivity of the key steroidogenic enzyme, cytochrome P450side chain cleavage, in sensory neural
pathways. J. Neurochem. 2003,86, 1233–1246. [CrossRef]
30.
Benmessahel, Y.; Troadec, J.D.; Cadepond, F.; Guennoun, R.; Hales, D.B.; Schumacher, M.; Groyer, G.
Downregulation of steroidogenic acute regulatory protein (StAR) gene expression by cyclic AMP in cultured
Schwann cells. Glia 2004,45, 213–228. [CrossRef]
31.
Papadopoulos, V.; Baraldi, M.; Guilarte, T.R.; Knudsen, T.B.; Lacapere, J.J.; Lindemann, P.; Norenberg, M.D.;
Nutt, D.; Weizman, A.; Zhang, M.R.; et al. Translocator protein (18kDa): New nomenclature for the peripheral-type
benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci.
2006
,27,
402–409. [CrossRef] [PubMed]
32.
Melcangi, R.C.; Magnaghi, V.; Galbiati, M.; Martini, L. Formation and effects of neuroactive steroids in the
central and peripheral nervous system. Int. Rev. Neurobiol. 2001,46, 145–176. [PubMed]
33.
Yokoi, H.; Tsuruo, Y.; Ishimura, K. Steroid 5alpha-reductase type 1 immunolocalized in the rat peripheral
nervous system and paraganglia. Histochem. J. 1998,30, 731–739. [CrossRef] [PubMed]
34.
Luu-The, V. Assessment of steroidogenesis and steroidogenic enzyme functions. J. Steroid Biochem. Mol. Biol.
2013,137, 176–182. [CrossRef] [PubMed]
35.
Caruso, D.; Pesaresi, M.; Abbiati, F.; Calabrese, D.; Giatti, S.; Garcia-Segura, L.M.; Melcangi, R.C. Comparison
of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral
nerve levels in male and female rats. Psychoneuroendocrinology 2013,38, 2278–2290. [CrossRef] [PubMed]
36.
Caruso, D.; Scurati, S.; Maschi, O.; De Angelis, L.; Roglio, I.; Giatti, S.; Garcia-Segura, L.M.; Melcangi, R.C.
Evaluation of neuroactive steroid levels by liquid chromatography-tandem mass spectrometry in central and
peripheral nervous system: Effect of diabetes. Neurochem. Int. 2008,52, 560–568. [CrossRef]
37.
Caruso, D.; Scurati, S.; Roglio, I.; Nobbio, L.; Schenone, A.; Melcangi, R.C. Neuroactive Steroid Levels in a
transgenic rat model of CMT1A Neuropathy. J. Mol. Neurosci. 2008,34, 249–253. [CrossRef]
38.
Pesaresi, M.; Maschi, O.; Giatti, S.; Garcia-Segura, L.M.; Caruso, D.; Melcangi, R.C. Sex differences in
neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. Horm. Behav.
2010
,57,
46–55. [CrossRef]
39.
Dong, F.; Xie, W.; Strong, J.A.; Zhang, J.M. Mineralocorticoid receptor blocker eplerenone reduces pain
behaviors
in vivo
and decreases excitability in small-diameter sensory neurons from local inflamed dorsal
root ganglia in vitro. Anesthesiology 2012,117, 1102–1112. [CrossRef]
40.
Ye, L.; Xie, W.; Strong, J.A.; Zhang, J.M. Blocking the mineralocorticoid receptor improves effectiveness of
steroid treatment for low back pain in rats. Anesthesiology 2014,121, 632–643. [CrossRef]
41.
Olbrich, L.; Wessel, L.; Balakrishnan-Renuka, A.; Boing, M.; Brand-Saberi, B.; Theiss, C. Rapid impact of
progesterone on the neuronal growth cone. Endocrinology 2013,154, 3784–3795. [CrossRef] [PubMed]
42.
Luo, H.; Liu, J.; Kang, D.; Cui, S. Ontogeny of estrogen receptor alpha, estrogen receptor beta and androgen
receptor, and their co-localization with Islet-1 in the dorsal root ganglia of sheep fetuses during gestation.
Histochem. Cell Biol. 2008,129, 525–533. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020,21, 9000 17 of 25
43.
Melcangi, R.C.; Magnaghi, V.; Galbiati, M.; Martini, L. Glial cells: A target for steroid hormones. Prog. Brain Res.
2001,132, 31–40. [PubMed]
44.
Melcangi, R.C.; Magnaghi, V.; Galbiati, M.; Martini, L. Steroid effects on the gene expression of peripheral
myelin proteins. Horm. Behav. 2001,40, 210–214. [CrossRef] [PubMed]
45.
Jung-Testas, I.; Schumacher, M.; Robel, P.; Baulieu, E.E. Demonstration of progesterone receptors in rat
Schwann cells. J. Steroid Biochem. Mol. Biol. 1996,58, 77–82. [CrossRef]
46.
Groyer, G.; Eychenne, B.; Girard, C.; Rajkowski, K.; Schumacher, M.; Cadepond, F. Expression and functional
state of the corticosteroid receptors and 11 beta-hydroxysteroid dehydrogenase type 2 in Schwann cells.
Endocrinology 2006,147, 4339–4350. [CrossRef]
47.
Al-Dahan, M.I.; Jalilian Tehrani, M.H.; Thalmann, R.H. Regulation of gamma-aminobutyric acidB (GABAB)
receptors in cerebral cortex during the estrous cycle. Brain Res. 1994,640, 33–39. [CrossRef]
48.
Al-Dahan, M.I.; Thalmann, R.H. Progesterone regulates gamma-aminobutyric acid B (GABAB) receptors in
the neocortex of female rats. Brain Res. 1996,727, 40–48. [CrossRef]
49.
Falkenstein, E.; Wehling, M. Nongenomically initiated steroid actions. Eur. J. Clin. Investig.
2000
,30 (Suppl. S3),
51–54. [CrossRef]
50.
Lambert, J.J.; Belelli, D.; Harney, S.C.; Peters, J.A.; Frenguelli, B.G. Modulation of native and recombinant
GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain Res. Rev.
2001
,37, 68–80.
[CrossRef]
51.
Lambert, J.J.; Belelli, D.; Peden, D.R.; Vardy, A.W.; Peters, J.A. Neurosteroid modulation of GABAA receptors.
Prog. Neurobiol. 2003,71, 67–80. [CrossRef] [PubMed]
52.
Maurice, T.; Urani, A.; Phan, V.L.; Romieu, P. The interaction between neuroactive steroids and the sigma1
receptor function: Behavioral consequences and therapeutic opportunities. Brain Res. Rev.
2001
,37, 116–132.
[CrossRef]
53.
Romieu, P.; Martin-Fardon, R.; Bowen, W.D.; Maurice, T. Sigma 1 receptor-related neuroactive steroids
modulate cocaine-induced reward. J. Neurosci. 2003,23, 3572–3576. [CrossRef] [PubMed]
54.
Rupprecht, R.; di Michele, F.; Hermann, B.; Strohle, A.; Lancel, M.; Romeo, E.; Holsboer, F. Neuroactive
steroids: Molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Rev.
2001,37, 59–67. [CrossRef]
55.
Magnaghi, V.; Ballabio, M.; Consoli, A.; Lambert, J.J.; Roglio, I.; Melcangi, R.C. GABA receptor-mediated
effects in the peripheral nervous system: A cross-interaction with neuroactive steroids. J. Mol. Neurosci.
2006
,
28, 89–102. [CrossRef]
56.
Coggeshall, R.E.; Carlton, S.M. Ultrastructural analysis of NMDA, AMPA, and kainate receptors on
unmyelinated and myelinated axons in the periphery. J. Comp. Neurol. 1998,391, 78–86. [CrossRef]
57. Verkhratsky, A.; Steinhauser, C. Ion channels in glial cells. Brain Res. Rev. 2000,32, 380–412. [CrossRef]
58.
Dememes, D.; Lleixa, A.; Dechesne, C.J. Cellular and subcellular localization of AMPA-selective glutamate
receptors in the mammalian peripheral vestibular system. Brain Res. 1995,671, 83–94. [CrossRef]
59.
Zhu, Y.; Bond, J.; Thomas, P. Identification, classification, and partial characterization of genes in humans
and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. USA
2003
,
100, 2237–2242. [CrossRef]
60.
Pang, Y.; Dong, J.; Thomas, P. Characterization, neurosteroid binding and brain distribution of human
membrane progesterone receptors delta and epsilon (mPRdelta and mPRepsilon) and mPRdelta involvement
in neurosteroid inhibition of apoptosis. Endocrinology 2013,154, 283–295. [CrossRef]
61.
Castelnovo, L.F.; Caffino, L.; Bonalume, V.; Fumagalli, F.; Thomas, P.; Magnaghi, V. Membrane Progesterone
Receptors (mPRs/PAQRs) Differently Regulate Migration, Proliferation, and Differentiation in Rat Schwann
Cells. J. Mol. Neurosci. 2020,70, 433–448. [CrossRef] [PubMed]
62.
Castelnovo, L.F.; Magnaghi, V.; Thomas, P. Expression of membrane progesterone receptors (mPRs) in rat
peripheral glial cell membranes and their potential role in the modulation of cell migration and protein
expression. Steroids 2019,142, 6–13. [CrossRef] [PubMed]
63.
Melcangi, R.C.; Giatti, S.; Pesaresi, M.; Calabrese, D.; Mitro, N.; Caruso, D.; Garcia-Segura, L.M. Role of
neuroactive steroids in the peripheral nervous system. Front. Endocrinol. (Lausanne)
2011
,2, 104. [CrossRef]
[PubMed]
64.
Colciago, A.; Bonalume, V.; Melfi, V.; Magnaghi, V. Genomic and Non-genomic Action of Neurosteroids in
the Peripheral Nervous System. Front. Neurosci. 2020,14, 796. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020,21, 9000 18 of 25
65.
Magnaghi, V.; Ballabio, M.; Gonzalez, L.C.; Leonelli, E.; Motta, M.; Melcangi, R.C. The synthesis of
glycoprotein Po and peripheral myelin protein 22 in sciatic nerve of male rats is modulated by testosterone
metabolites. Brain Res. Mol. Brain Res. 2004,126, 67–73. [CrossRef]
66.
Melcangi, R.C.; Leonelli, E.; Magnaghi, V.; Gherardi, G.; Nobbio, L.; Schenone, A. Mifepristone (RU 38486)
influences expression of glycoprotein Po and morphological parameters at the level of rat sciatic nerve:
In vivo observations. Exp. Neurol. 2003,184, 930–938. [CrossRef]
67.
Cavarretta, I.T.; Martini, L.; Motta, M.; Smith, C.L.; Melcangi, R.C. SRC-1 is involved in the control of the
gene expression of myelin protein Po. J. Mol. Neurosci. 2004,24, 217–226. [CrossRef]
68.
Giatti, S.; Romano, S.; Pesaresi, M.; Cermenati, G.; Mitro, N.; Caruso, D.; Tetel, M.J.; Garcia-Segura, L.M.;
Melcangi, R.C. Neuroactive steroids and the peripheral nervous system: An update. Steroids
2015
,103, 23–30.
[CrossRef]
69.
Magnaghi, V.; Cavarretta, I.; Galbiati, M.; Martini, L.; Melcangi, R.C. Neuroactive steroids and peripheral
myelin proteins. Brain Res. Rev. 2001,37, 360–371. [CrossRef]
70.
Melfi, S.; Montt Guevara, M.M.; Bonalume, V.; Ruscica, M.; Colciago, A.; Simoncini, T.; Magnaghi, V. Src and
phospho-FAK kinases are activated by allopregnanolone promoting Schwann cell motility, morphology and
myelination. J. Neurochem. 2017,141, 165–178. [CrossRef]
71.
Bartolami, S.; Auge, C.; Travo, C.; Venteo, S.; Knipper, M.; Sans, A. Vestibular Schwann cells are a
distinct subpopulation of peripheral glia with specific sensitivity to growth factors and extracellular matrix
components. J. Neurobiol. 2003,57, 270–290. [CrossRef] [PubMed]
72.
Lapchak, P.A.; Araujo, D.M. Preclinical development of neurosteroids as neuroprotective agents for the
treatment of neurodegenerative diseases. Int. Rev. Neurobiol. 2001,46, 379–397. [PubMed]
73.
Giatti, S.; Caruso, D.; Boraso, M.; Abbiati, F.; Ballarini, E.; Calabrese, D.; Pesaresi, M.; Rigolio, R.;
Santos-Galindo, M.; Viviani, B.; et al. Neuroprotective Effects of Progesterone in Chronic Experimental
Autoimmune Encephalomyelitis. J. Neuroendocrinol. 2012,24, 851–861. [CrossRef] [PubMed]
74.
Azcoitia, I.; Sierra, A.; Garcia-Segura, L.M. Neuroprotective effects of estradiol in the adult rat hippocampus:
Interaction with insulin-like growth factor-I signalling. J. Neurosci. Res. 1999,58, 815–822. [CrossRef]
75.
Azcoitia, I.; Sierra, A.; Veiga, S.; Honda, S.; Harada, N.; Garcia-Segura, L.M. Brain aromatase is neuroprotective.
J. Neurobiol. 2001,47, 318–329. [CrossRef]
76.
Ciriza, I.; Azcoitia, I.; Garcia-Segura, L.M. Reduced progesterone metabolites protect rat hippocampal
neurones from kainic acid excitotoxicity in vivo. J. Neuroendocrinol. 2004,16, 58–63. [CrossRef]
77.
Ciriza, I.; Carrero, P.; Frye, C.A.; Garcia-Segura, L.M. Reduced metabolites mediate neuroprotective effects of
progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera)
is not neuroprotective. J. Neurobiol. 2006,66, 916–928. [CrossRef]
78.
Labombarda, F.; Gonzalez, S.; Gonzalez Deniselle, M.C.; Garay, L.; Guennoun, R.; Schumacher, M.;
De Nicola, A.F. Progesterone increases the expression of myelin basic protein and the number of cells showing
NG2 immunostaining in the lesioned spinal cord. J. Neurotrauma 2006,23, 181–192. [CrossRef]
79.
Labombarda, F.; Gonzalez, S.L.; Lima, A.; Roig, P.; Guennoun, R.; Schumacher, M.; de Nicola, A.F. Effects of
progesterone on oligodendrocyte progenitors, oligodendrocyte transcription factors, and myelin proteins
following spinal cord injury. Glia 2009,57, 884–897. [CrossRef]
80.
Cutler, S.M.; Cekic, M.; Miller, D.M.; Wali, B.; VanLandingham, J.W.; Stein, D.G. Progesterone improves acute
recovery after traumatic brain injury in the aged rat. J. Neurotrauma 2007,24, 1475–1486. [CrossRef]
81.
Bourque, M.; Morissette, M.; Al Sweidi, S.; Caruso, D.; Melcangi, R.C.; Di Paolo, T. Neuroprotective Effect of
Progesterone in MPTP-Treated Male Mice. Neuroendocrinology 2016,103, 300–314. [CrossRef] [PubMed]
82.
Kumar, P.; Khan, A.; Deshmukh, R.; Lal Sharma, P. Role of neurosteroids in experimental 3-nitropropionic
acid induced neurotoxicity in rats. Eur. J. Pharmacol. 2014,723, 38–45. [CrossRef] [PubMed]
83.
Schumacher, M.; Sitruk-Ware, R.; De Nicola, A.F. Progesterone and progestins: Neuroprotection and myelin
repair. Curr. Opin. Pharmacol. 2008,8, 740–746. [CrossRef] [PubMed]
84.
Melcangi, R.C.; Giatti, S.; Garcia-Segura, L.M. Levels and actions of neuroactive steroids in the nervous
system under physiological and pathological conditions: Sex-specific features. Neurosci. Biobehav. Rev.
2016
,
67, 25–40. [CrossRef]
85.
Lloyd-Evans, E.; Waller-Evans, H. Biosynthesis and signalling functions of central and peripheral nervous
system neurosteroids in health and disease. Essays Biochem. 2020. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 19 of 25
86.
Pesaresi, M.; Giatti, S.; Calabrese, D.; Maschi, O.; Caruso, D.; Melcangi, R.C. Dihydroprogesterone increases
the gene expression of myelin basic protein in spinal cord of diabetic rats. J. Mol. Neurosci.
2010
,42, 135–139.
[CrossRef]
87.
Melcangi, R.C.; Mensah-Nyagan, A.G. Neuroprotective effects of neuroactive steroids in the spinal cord and
peripheral nerves. J. Mol. Neurosci. 2006,28, 1–2. [CrossRef]
88.
Hara, Y.; Ochiai, N.; Abe, I.; Ichimura, H.; Saijilafu; Nishiura, Y. Effect of progesterone on recovery from
nerve injury during leg lengthening in rats. J. Bone Jt. Surg. Br. 2007,89, 830–835. [CrossRef]
89.
Giatti, S.; Mastrangelo, R.; D’Antonio, M.; Pesaresi, M.; Romano, S.; Diviccaro, S.; Caruso, D.; Mitro, N.;
Melcangi, R.C. Neuroactive steroids and diabetic complications in the nervous system. Front. Neuroendocrinol.
2018,48, 58–69. [CrossRef]
90.
Melcangi, R.C.; Garcia-Segura, L.M. Therapeutic approaches to peripheral neuropathy based on neuroactive
steroids. Expert Rev. Neurother. 2006,6, 1121–1125. [CrossRef]
91.
Pesaresi, M.; Giatti, S.; Cavaletti, G.; Abbiati, F.; Calabrese, D.; Lombardi, R.; Bianchi, R.; Lauria, G.;
Caruso, D.; Garcia-Segura, L.M.; et al. Sex-dimorphic effects of dehydroepiandrosterone in diabetic
neuropathy. Neuroscience 2011,199, 401–409. [CrossRef] [PubMed]
92.
Roglio, I.; Giatti, S.; Pesaresi, M.; Bianchi, R.; Cavaletti, G.; Lauria, G.; Garcia-Segura, L.M.; Melcangi, R.C.
Neuroactive steroids and peripheral neuropathy. Brain Res. Rev. 2008,57, 460–469. [CrossRef] [PubMed]
93.
Schumacher, M.; Guennoun, R.; Stein, D.G.; De Nicola, A.F. Progesterone: Therapeutic opportunities for
neuroprotection and myelin repair. Pharmacol. Ther. 2007,116, 77–106. [CrossRef] [PubMed]
94.
Melcangi, R.C.; Giatti, S.; Calabrese, D.; Pesaresi, M.; Cermenati, G.; Mitro, N.; Viviani, B.; Garcia-Segura, L.M.;
Caruso, D. Levels and actions of progesterone and its metabolites in the nervous system during physiological
and pathological conditions. Prog. Neurobiol. 2014,113, 56–69. [CrossRef]
95.
Giatti, S.; Garcia-Segura, L.M.; Barreto, G.E.; Melcangi, R.C. Neuroactive steroids, neurosteroidogenesis and
sex. Prog. Neurobiol. 2019,176, 1–17. [CrossRef]
96.
Mitro, N.; Cermenati, G.; Audano, M.; Giatti, S.; Pesaresi, M.; Pedretti, S.; Spezzano, R.; Caruso, D.;
Melcangi, R.C. Sterol regulatory element binding protein-1C knockout mice show altered neuroactive steroid
levels in sciatic nerve. J. Neurochem. 2017,142, 420–428. [CrossRef]
97.
Sugimoto, K.; Murakawa, Y.; Sima, A.A. Diabetic neuropathy–a continuing enigma. Diabetes Metab. Res. Rev.
2000,16, 408–433. [CrossRef]
98.
Vinik, A.I.; Park, T.S.; Stansberry, K.B.; Pittenger, G.L. Diabetic neuropathies. Diabetologia
2000
,43, 957–973.
[CrossRef]
99.
Eckersley, L. Role of the Schwann cell in diabetic neuropathy. Int. Rev. Neurobiol.
2002
,50, 293–321. [CrossRef]
100.
Greene, D.A.; Lattimer-Greene, S.; Sima, A.A. Pathogenesis of diabetic neuropathy: Role of altered
phosphoinositide metabolism. Crit. Rev. Neurobiol. 1989,5, 143–219.
101.
Leonelli, E.; Bianchi, R.; Cavaletti, G.; Caruso, D.; Crippa, D.; Garcia-Segura, L.M.; Lauria, G.; Magnaghi, V.;
Roglio, I.; Melcangi, R.C. Progesterone and its derivatives are neuroprotective agents in experimental diabetic
neuropathy: A multimodal analysis. Neuroscience 2007,144, 1293–1304. [CrossRef] [PubMed]
102.
Lauria, G.; Lombardi, R.; Borgna, M.; Penza, P.; Bianchi, R.; Savino, C.; Canta, A.; Nicolini, G.; Marmiroli, P.;
Cavaletti, G. Intraepidermal nerve fiber density in rat foot pad: Neuropathologic-neurophysiologic correlation.
J. Peripher. Nerv. Syst. 2005,10, 202–208. [CrossRef] [PubMed]
103.
Lauria, G.; Morbin, M.; Lombardi, R.; Borgna, M.; Mazzoleni, G.; Sghirlanzoni, A.; Pareyson, D.
Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology
2003
,
61, 631–636. [CrossRef] [PubMed]
104.
Pesaresi, M.; Giatti, S.; Cavaletti, G.; Abbiati, F.; Calabrese, D.; Bianchi, R.; Caruso, D.; Garcia-Segura, L.M.;
Melcangi, R.C. Sex differences in the manifestation of peripheral diabetic neuropathy in gonadectomized rats:
A correlation with the levels of neuroactive steroids in the sciatic nerve. Exp. Neurol.
2011
,228, 215–221.
[CrossRef]
105.
Periquet, M.I.; Novak, V.; Collins, M.P.; Nagaraja, H.N.; Erdem, S.; Nash, S.M.; Freimer, M.L.; Sahenk, Z.;
Kissel, J.T.; Mendell, J.R. Painful sensory neuropathy: Prospective evaluation using skin biopsy. Neurology
1999,53, 1641–1647. [CrossRef]
106.
Roglio, I.; Bianchi, R.; Giatti, S.; Cavaletti, G.; Caruso, D.; Scurati, S.; Crippa, D.; Garcia-Segura, L.M.;
Camozzi, F.; Lauria, G.; et al. Testosterone derivatives are neuroprotective agents in experimental diabetic
neuropathy. Cell. Mol. Life Sci. 2007,64, 1158–1168. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 20 of 25
107.
Yagihashi, S. Pathogenetic mechanisms of diabetic neuropathy: Lessons from animal models. J. Peripher.
Nerv. Syst. 1997,2, 113–132.
108.
Veiga, S.; Leonelli, E.; Beelke, M.; Garcia-Segura, L.M.; Melcangi, R.C. Neuroactive steroids prevent peripheral
myelin alterations induced by diabetes. Neurosci. Lett. 2006,402, 150–153. [CrossRef]
109.
Cermenati, G.; Abbiati, F.; Cermenati, S.; Brioschi, E.; Volonterio, A.; Cavaletti, G.; Saez, E.; De Fabiani, E.;
Crestani, M.; Garcia-Segura, L.M.; et al. Diabetes-induced myelin abnormalities are associated with an
altered lipid pattern: Protective effects of LXR activation. J. Lipid Res. 2012,53, 300–310. [CrossRef]
110.
Pesaresi, M.; Giatti, S.; Spezzano, R.; Romano, S.; Diviccaro, S.; Borsello, T.; Mitro, N.; Caruso, D.;
Garcia-Segura, L.M.; Melcangi, R.C. Axonal transport in a peripheral diabetic neuropathy model:
Sex-dimorphic features. Biol. Sex Differ. 2018,9, 6. [CrossRef]
111.
Yorek, M.A.; Coppey, L.J.; Gellett, J.S.; Davidson, E.P.; Bing, X.; Lund, D.D.; Dillon, J.S. Effect of treatment of
diabetic rats with dehydroepiandrosterone on vascular and neural function. Am. J. Physiol. Endocrinol. Metab.
2002,283, E1067–E1075. [CrossRef] [PubMed]
112.
Mitro, N.; Cermenati, G.; Brioschi, E.; Abbiati, F.; Audano, M.; Giatti, S.; Crestani, M.; De Fabiani, E.;
Azcoitia, I.; Garcia-Segura, L.M.; et al. Neuroactive steroid treatment modulates myelin lipid profile in
diabetic peripheral neuropathy. J. Steroid Biochem. Mol. Biol. 2014,143, 115–121. [CrossRef] [PubMed]
113.
Cermenati, G.; Audano, M.; Giatti, S.; Carozzi, V.; Porretta-Serapiglia, C.; Pettinato, E.; Ferri, C.; D’Antonio, M.;
De Fabiani, E.; Crestani, M.; et al. Lack of sterol regulatory element binding factor-1c imposes glial Fatty
Acid utilization leading to peripheral neuropathy. Cell Metab. 2015,21, 571–583. [CrossRef] [PubMed]
114.
Cermenati, G.; Giatti, S.; Cavaletti, G.; Bianchi, R.; Maschi, O.; Pesaresi, M.; Abbiati, F.; Volonterio, A.; Saez, E.;
Caruso, D.; et al. Activation of the liver X receptor increases neuroactive steroid levels and protects from
diabetes-induced peripheral neuropathy. J. Neurosci. 2010,30, 11896–11901. [CrossRef] [PubMed]
115.
Giatti, S.; Pesaresi, M.; Cavaletti, G.; Bianchi, R.; Carozzi, V.; Lombardi, R.; Maschi, O.; Lauria, G.;
Garcia-Segura, L.M.; Caruso, D.; et al. Neuroprotective effects of a ligand of translocator protein-18kDa
(Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009,164, 520–529. [CrossRef] [PubMed]
116.
Marmiroli, P.; Scuteri, A.; Cornblath, D.R.; Cavaletti, G. Pain in chemotherapy-induced peripheral
neurotoxicity. J. Peripher. Nerv. Syst. 2017,22, 156–161. [CrossRef]
117.
Staff, N.P.; Grisold, A.; Grisold, W.; Windebank, A.J. Chemotherapy-induced peripheral neuropathy: A current
review. Ann. Neurol. 2017,81, 772–781. [CrossRef] [PubMed]
118.
Carozzi, V.A.; Canta, A.; Chiorazzi, A. Chemotherapy-induced peripheral neuropathy: What do we know
about mechanisms? Neurosci. Lett. 2015,596, 90–107. [CrossRef]
119.
Roglio, I.; Bianchi, R.; Camozzi, F.; Carozzi, V.; Cervellini, I.; Crippa, D.; Lauria, G.; Cavaletti,G.; Melcangi, R.C.
Docetaxel-induced peripheral neuropathy: Protective effects of dihydroprogesterone and progesterone in an
experimental model. J. Peripher. Nerv. Syst. 2009,14, 36–44. [CrossRef]
120.
Meyer, L.; Patte-Mensah, C.; Taleb, O.; Mensah-Nyagan, A.G. Cellular and functional evidence for a protective
action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell. Mol. Life Sci.
2010,67, 3017–3034. [CrossRef]
121.
Bramley, J.C.; Collins, S.V.; Clark, K.B.; Buchser, W.J. Avian axons undergo Wallerian degeneration after
injury and stress. J. Comp. Physiol. A Neuroethol. Sens. Neural Behav. Physiol.
2016
,202, 813–822. [CrossRef]
[PubMed]
122.
Rosenberg, A.F.; Wolman, M.A.; Franzini-Armstrong, C.; Granato, M.
In vivo
nerve-macrophage interactions
following peripheral nerve injury. J. Neurosci. 2012,32, 3898–3909. [CrossRef] [PubMed]
123.
Roglio, I.; Bianchi, R.; Gotti, S.; Scurati, S.; Giatti, S.; Pesaresi, M.; Caruso, D.; Panzica, G.C.; Melcangi, R.C.
Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush
injury. Neuroscience 2008,155, 673–685. [CrossRef]
124.
Vita, G.; Dattola, R.; Girlanda, P.; Oteri, G.; Lo Presti, F.; Messina, C. Effects of steroid hormones on muscle
reinnervation after nerve crush in rabbit. Exp. Neurol. 1983,80, 279–287. [CrossRef]
125.
Yu, W.H. Effect of testosterone on the regeneration of the hypoglossal nerve in rats. Exp. Neurol.
1982
,77,
129–141. [CrossRef]
126.
Huppenbauer, C.B.; Tanzer, L.; DonCarlos, L.L.; Jones, K.J. Gonadal steroid attenuation of developing
hamster facial motoneuron loss by axotomy: Equal efficacy of testosterone, dihydrotestosterone, and 17-beta
estradiol. J. Neurosci. 2005,25, 4004–4013. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 21 of 25
127.
Jones, K.J.; Brown, T.J.; Damaser, M. Neuroprotective effects of gonadal steroids on regenerating peripheral
motoneurons. Brain Res. Rev. 2001,37, 372–382. [CrossRef]
128.
Ayhan, S.; Markal, N.; Siemionow, K.; Araneo, B.; Siemionow, M. Effect of subepineurial dehydroepiandrosterone
treatment on healing of transected nerves repaired with the epineurial sleeve technique. Microsurgery
2003
,
23, 49–55. [CrossRef]
129.
Gudemez, E.; Ozer, K.; Cunningham, B.; Siemionow, K.; Browne, E.; Siemionow, M. Dehydroepiandrosterone
as an enhancer of functional recovery following crush injury to rat sciatic nerve. Microsurgery
2002
,22,
234–241. [CrossRef]
130.
Giatti, S.; Diviccaro, S.; Garcia-Segura, L.M.; Melcangi, R.C. Sex differences in the brain expression of
steroidogenic molecules under basal conditions and after gonadectomy. J. Neuroendocrinol.
2019
, e12736.
[CrossRef]
131.
Caruso, D.; Pesaresi, M.; Maschi, O.; Giatti, S.; Garcia-Segura, L.M.; Melcangi, R.C. Effects of Short- and
Long-Term Gonadectomy on Neuroactive Steroid Levels in the Central and Peripheral Nervous System of
Male and Female Rats. J. Neuroendocrinol. 2010,22, 1137–1147. [CrossRef] [PubMed]
132.
Magnaghi, V.; Veiga, S.; Ballabio, M.; Gonzalez, L.C.; Garcia-Segura, L.M.; Melcangi, R.C. Sex-dimorphic
effects of progesterone and its reduced metabolites on gene expression of myelin proteins by rat Schwann
cells. J. Peripher. Nerv. Syst. 2006,11, 111–118. [CrossRef] [PubMed]
133.
Giatti, S.; Diviccaro, S.; Serafini, M.M.; Caruso, D.; Garcia-Segura, L.M.; Viviani, B.; Melcangi, R.C.
Sex differences in steroid levels and steroidogenesis in the nervous system: Physiopathological role.
Front. Neuroendocrinol. 2019, 100804. [CrossRef] [PubMed]
134.
Basit, A.; Hydrie, M.Z.; Hakeem, R.; Ahmedani, M.Y.; Masood, Q. Frequency of chronic complications of
type II diabetes. J. Coll. Physicians Surg. Pak. 2004,14, 79–83.
135.
Booya, F.; Bandarian, F.; Larijani, B.; Pajouhi, M.; Nooraei, M.; Lotfi, J. Potential risk factors for diabetic
neuropathy: A case control study. BMC Neurol. 2005,5, 24. [CrossRef]
136.
Aaberg, M.L.; Burch, D.M.; Hud, Z.R.; Zacharias, M.P. Gender differences in the onset of diabetic neuropathy.
J. Diabetes Complicat. 2008,22, 83–87. [CrossRef]
137.
Kiziltan, M.E.; Gunduz, A.; Kiziltan, G.; Akalin, M.A.; Uzun, N. Peripheral neuropathy in patients with
diabetic foot ulcers: Clinical and nerve conduction study. J. Neurol. Sci. 2007,258, 75–79. [CrossRef]
138.
Kiziltan, M.E.; Benbir, G. Clinical and electrophysiological differences in male and female patients with
diabetic foot. Diabetes Res. Clin. Pract. 2008,79, E17–E18. [CrossRef]
139.
Stenberg, L.; Dahlin, L.B. Gender differences in nerve regeneration after sciatic nerve injury and repair in
healthy and in type 2 diabetic Goto-Kakizaki rats. BMC Neurosci. 2014,15, 107. [CrossRef]
140.
Lakocevic, M.B.; Platisa, M.M.; Sumarac, Z.R.; Suvajdzic, N.D.; Macukanovic, L.D.; Petakov, M.S. Peripheral
neural response and sex hormones in type 1 Gaucher disease. J. Med. Biochem. 2020,39, 60–65. [CrossRef]
141.
Mehta, S.A.; Ahmed, A.; Laverty, M.; Holzman, R.S.; Valentine, F.; Sivapalasingam, S. Sex differences in the
incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin. Infect. Dis.
2011
,
53, 490–496. [CrossRef] [PubMed]
142.
Jensen, T.S.; Finnerup, N.B. Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and
mechanisms. Lancet Neurol. 2014,13, 924–935. [CrossRef]
143.
Campbell, J.N.; Meyer, R.A. Mechanisms of neuropathic pain. Neuron
2006
,52, 77–92. [CrossRef] [PubMed]
144.
Finnerup, N.B. A review of central neuropathic pain states. Curr. Opin. Anaesthesiol.
2008
,21, 586–589.
[CrossRef] [PubMed]
145.
Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpaa, M.;
Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and
meta-analysis. Lancet Neurol. 2015,14, 162–173. [CrossRef]
146.
Costigan, M.; Scholz, J.; Woolf, C.J. Neuropathic pain: A maladaptive response of the nervous system to
damage. Annu. Rev. Neurosci. 2009,32, 1–32. [CrossRef]
147.
Basbaum, A.I.; Bautista, D.M.; Scherrer, G.; Julius, D. Cellular and molecular mechanisms of pain. Cell
2009
,
139, 267–284. [CrossRef]
148.
Truini, A.; Cruccu, G. Pathophysiological mechanisms of neuropathic pain. Neurol Sci
2006
,27 (Suppl. S2),
S179–S182. [CrossRef]
149.
Woolf, C.J.; Salter, M.W. Neuronal plasticity: Increasing the gain in pain. Science
2000
,288, 1765–1769.
[CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 22 of 25
150.
Wei, Z.; Fei, Y.; Su, W.; Chen, G. Emerging Role of Schwann Cells in Neuropathic Pain: Receptors, Glial Mediators
and Myelination. Front. Cell Neurosci. 2019,13, 116. [CrossRef]
151.
Garcia-Segura, L.M.; Melcangi, R.C. Steroids and glial cell function. Glia
2006
,54, 485–498. [CrossRef]
[PubMed]
152.
Schumacher, M.; Mattern, C.; Ghoumari, A.; Oudinet, J.P.; Liere, P.; Labombarda, F.; Sitruk-Ware, R.;
De Nicola, A.F.; Guennoun, R. Revisiting the roles of progesterone and allopregnanolone in the nervous
system: Resurgence of the progesterone receptors. Prog. Neurobiol. 2014,113, 6–39. [CrossRef] [PubMed]
153.
Giatti, S.; Diviccaro, S.; Falvo, E.; Garcia-Segura, L.M.; Melcangi, R.C. Physiopathological role of the enzymatic
complex 5alpha-reductase and 3alpha/beta-hydroxysteroid oxidoreductase in the generation of progesterone
and testosterone neuroactive metabolites. Front. Neuroendocrinol. 2020,57, 100836. [CrossRef] [PubMed]
154.
Giatti, S.; Garcia-Segura, L.M.; Melcangi, R.C. New steps forward in the neuroactive steroid field. J. Steroid
Biochem. Mol. Biol. 2015,153, 127–134. [CrossRef] [PubMed]
155. Sibilia, J. Corticosteroids and inflammation. Rev. Prat. 2003,53, 495–501. [PubMed]
156.
Wang, S.; Lim, G.; Zeng, Q.; Sung, B.; Yang, L.; Mao, J. Central glucocorticoid receptors modulate the
expression and function of spinal NMDA receptors after peripheral nerve injury. J. Neurosci.
2005
,25,
488–495. [CrossRef] [PubMed]
157.
Alexander, J.K.; DeVries, A.C.; Kigerl, K.A.; Dahlman, J.M.; Popovich, P.G. Stress exacerbates neuropathic
pain via glucocorticoid and NMDA receptor activation. Brain Behav. Immun. 2009,23, 851–860. [CrossRef]
158.
Le Coz, G.M.; Anton, F.; Hanesch, U. Glucocorticoid-mediated enhancement of glutamatergic transmission
may outweigh anti-inflammatory effects under conditions of neuropathic pain. PLoS ONE
2014
,9, e91393.
[CrossRef]
159.
Lerch, J.K.; Puga, D.A.; Bloom, O.; Popovich, P.G. Glucocorticoids and macrophage migration inhibitory
factor (MIF) are neuroendocrine modulators of inflammation and neuropathic pain after spinal cord injury.
Semin. Immunol. 2014,26, 409–414. [CrossRef]
160.
Coronel, M.F.; Labombarda, F.; Roig, P.; Villar, M.J.; De Nicola, A.F.; Gonzalez, S.L. Progesterone prevents
nerve injury-induced allodynia and spinal NMDA receptor upregulation in rats. Pain Med.
2011
,12,
1249–1261. [CrossRef]
161. Coronel, M.F.; Labombarda, F.; Villar, M.J.; De Nicola, A.F.; Gonzalez, S.L. Progesterone prevents allodynia
after experimental spinal cord injury. J. Pain 2011,12, 71–83. [CrossRef] [PubMed]
162.
Coronel, M.F.; Labombarda, F.; De Nicola, A.F.; Gonzalez, S.L. Progesterone reduces the expression of spinal
cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central
neuropathic pain. Eur. J. Pain 2014,18, 348–359. [CrossRef] [PubMed]
163.
Meyer, L.; Patte-Mensah, C.; Taleb, O.; Mensah-Nyagan, A.G. Allopregnanolone prevents and suppresses
oxaliplatin-evoked painful neuropathy: Multi-parametric assessment and direct evidence. Pain
2011
,152,
170–181. [CrossRef] [PubMed]
164.
Meyer, L.; Taleb, O.; Patte-Mensah, C.; Mensah-Nyagan, A.G. Neurosteroids and neuropathic pain management:
Basic evidence and therapeutic perspectives. Front. Neuroendocrinol. 2019,55, 100795. [CrossRef]
165.
Pathirathna, S.; Todorovic, S.M.; Covey, D.F.; Jevtovic-Todorovic, V. 5alpha-reduced neuroactive steroids
alleviate thermal and mechanical hyperalgesia in rats with neuropathic pain. Pain
2005
,117, 326–339.
[CrossRef]
166.
Coronel, M.F.; Sanchez Granel, M.L.; Raggio, M.C.; Adler, N.S.; De Nicola, A.F.; Labombarda, F.; Gonzalez, S.L.
Temporal changes in the expression of the translocator protein TSPO and the steroidogenic enzyme
5alpha-reductase in the dorsal spinal cord of animals with neuropathic pain: Effects of progesterone
administration. Neurosci. Lett. 2016,624, 23–28. [CrossRef]
167.
Afrazi, S.; Esmaeili-Mahani, S.; Sheibani, V.; Abbasnejad, M. Neurosteroid allopregnanolone attenuates
high glucose-induced apoptosis and prevents experimental diabetic neuropathic pain:
In vitro
and
in vivo
studies. J. Steroid Biochem. Mol. Biol. 2014,139, 98–103. [CrossRef]
168.
Jarahi, M.; Sheibani, V.; Safakhah, H.A.; Torkmandi, H.; Rashidy-Pour, A. Effects of progesterone on
neuropathic pain responses in an experimental animal model for peripheral neuropathy in the rat:
A behavioral and electrophysiological study. Neuroscience 2014,256, 403–411. [CrossRef]
169.
Belelli, D.; Lambert, J.J. Neurosteroids: Endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci.
2005,6, 565–575. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 23 of 25
170.
Meyer, L.; Venard, C.; Schaeffer, V.; Patte-Mensah, C.; Mensah-Nyagan, A.G. The biological activity of
3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds
after sciatic nerve injury. Neurobiol. Dis. 2008,30, 30–41. [CrossRef]
171.
Miguel, C.A.; Raggio, M.C.; Villar, M.J.; Gonzalez, S.L.; Coronel, M.F. Anti-allodynic and anti-inflammatory
effects of 17alpha-hydroxyprogesterone caproate in oxaliplatin-induced peripheral neuropathy. J. Peripher.
Nerv. Syst. 2019,24, 100–110. [CrossRef] [PubMed]
172.
White, D.M.; Cousins, M.J. Effect of subcutaneous administration of calcium channel blockers on nerve
injury-induced hyperalgesia. Brain Res. 1998,801, 50–58. [CrossRef]
173.
Dogrul, A.; Gardell, L.R.; Ossipov, M.H.; Tulunay, F.C.; Lai, J.; Porreca, F. Reversal of experimental neuropathic
pain by T-type calcium channel blockers. Pain 2003,105, 159–168. [CrossRef]
174.
Todorovic, S.M.; Meyenburg, A.; Jevtovic-Todorovic, V. Mechanical and thermal antinociception in rats
following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res.
2002
,951,
336–340. [CrossRef]
175.
Hamidi, G.A.; Ramezani, M.H.; Arani, M.N.; Talaei, S.A.; Mesdaghinia, A.; Banafshe, H.R. Ethosuximide
reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model
of neuropathic pain. Eur. J. Pharmacol. 2012,674, 260–264. [CrossRef] [PubMed]
176.
Pathirathna, S.; Brimelow, B.C.; Jagodic, M.M.; Krishnan, K.; Jiang, X.; Zorumski, C.F.; Mennerick, S.;
Covey, D.F.; Todorovic, S.M.; Jevtovic-Todorovic, V. New evidence that both T-type calcium channels and
GABAA channels are responsible for the potent peripheral analgesic effects of 5alpha-reduced neuroactive
steroids. Pain 2005,114, 429–443. [CrossRef]
177.
De la Puente, B.; Nadal, X.; Portillo-Salido, E.; Sanchez-Arroyos, R.; Ovalle, S.; Palacios, G.; Muro, A.;
Romero, L.; Entrena, J.M.; Baeyens, J.M.; et al. Sigma-1 receptors regulate activity-induced spinal sensitization
and neuropathic pain after peripheral nerve injury. Pain 2009,145, 294–303. [CrossRef]
178.
Peng, H.Y.; Chen, G.D.; Lee, S.D.; Lai, C.Y.; Chiu, C.H.; Cheng, C.L.; Chang, Y.S.; Hsieh, M.C.; Tung, K.C.;
Lin, T.B. Neuroactive steroids inhibit spinal reflex potentiation by selectively enhancing specific spinal
GABA(A) receptor subtypes. Pain 2009,143, 12–20. [CrossRef]
179.
Vergnano, A.M.; Schlichter, R.; Poisbeau, P. PKC activation sets an upper limit to the functional plasticity
of GABAergic transmission induced by endogenous neurosteroids. Eur. J. Neurosci.
2007
,26, 1173–1182.
[CrossRef]
180.
Puia, G.; Ravazzini, F.; Castelnovo, L.F.; Magnaghi, V. PKCepsilon and allopregnanolone: Functional cross-talk
at the GABAA receptor level. Front. Cell Neurosci. 2015,9, 83. [CrossRef]
181.
Bonalume, V.; Caffino, L.; Castelnovo, L.F.; Faroni, A.; Giavarini, F.; Liu, S.; Caruso, D.; Schmelz, M.;
Fumagalli, F.; Carr, R.W.; et al. Schwann Cell Autocrine and Paracrine Regulatory Mechanisms, Mediated
by Allopregnanolone and BDNF, Modulate PKCepsilon in Peripheral Sensory Neurons. Cells
2020
,9, 1874.
[CrossRef] [PubMed]
182.
Kibaly, C.; Patte-Mensah, C.; Mensah-Nyagan, A.G. Molecular and neurochemical evidence for the
biosynthesis of dehydroepiandrosterone in the adult rat spinal cord. J. Neurochem.
2005
,93, 1220–1230.
[CrossRef] [PubMed]
183.
Kibaly, C.; Meyer, L.; Patte-Mensah, C.; Mensah-Nyagan, A.G. Biochemical and functional evidence for
the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord.
FASEB J. 2008,22, 93–104. [CrossRef] [PubMed]
184.
Patte-Mensah, C.; Penning, T.M.; Mensah-Nyagan, A.G. Anatomical and cellular localization of neuroactive
5 alpha/3 alpha-reduced steroid-synthesizing enzymes in the spinal cord. J. Comp. Neurol.
2004
,477, 286–299.
[CrossRef]
185.
Patte-Mensah, C.; Meyer, L.; Schaeffer, V.; Mensah-Nyagan, A.G. Selective regulation of 3 alpha-hydroxysteroid
oxido-reductase expression in dorsal root ganglion neurons: A possible mechanism to cope with peripheral
nerve injury-induced chronic pain. Pain 2010,150, 522–534. [CrossRef]
186.
Patte-Mensah, C.; Kibaly, C.; Boudard, D.; Schaeffer, V.; Begle, A.; Saredi, S.; Meyer, L.; Mensah-Nyagan, A.G.
Neurogenic pain and steroid synthesis in the spinal cord. J. Mol. Neurosci. 2006,28, 17–31. [CrossRef]
187.
Mensah-Nyagan, A.G.; Kibaly, C.; Schaeffer, V.; Venard, C.; Meyer, L.; Patte-Mensah, C. Endogenous steroid
production in the spinal cord and potential involvement in neuropathic pain modulation. J. Steroid Biochem.
Mol. Biol. 2008,109, 286–293. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 24 of 25
188.
Mensah-Nyagan, A.G.; Meyer, L.; Schaeffer, V.; Kibaly, C.; Patte-Mensah, C. Evidence for a key role of steroids
in the modulation of pain. Psychoneuroendocrinology 2009,34 (Suppl. S1), S169–S177. [CrossRef]
189.
Patte-Mensah, C.; Kibaly, C.; Mensah-Nyagan, A.G. Substance P inhibits progesterone conversion to
neuroactive metabolites in spinal sensory circuit: A potential component of nociception. Proc. Natl. Acad.
Sci. USA 2005,102, 9044–9049. [CrossRef]
190.
Choi, S.R.; Beitz, A.J.; Lee, J.H. Inhibition of Cytochrome P450 Side-Chain Cleavage Attenuates the
Development of Mechanical Allodynia by Reducing Spinal D-Serine Production in a Murine Model of
Neuropathic Pain. Front. Pharmacol. 2019,10, 1439. [CrossRef]
191.
Choi, S.R.; Beitz, A.J.; Lee, J.H. Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a
mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation. Biomed. Pharmacother.
2019
,
118, 109299. [CrossRef] [PubMed]
192.
Wei, X.H.; Wei, X.; Chen, F.Y.; Zang, Y.; Xin, W.J.; Pang, R.P.; Chen, Y.; Wang, J.; Li, Y.Y.; Shen, K.F.; et al.
The upregulation of translocator protein (18 kDa) promotes recovery from neuropathic pain in rats. J. Neurosci.
2013,33, 1540–1551. [CrossRef] [PubMed]
193.
Jin, S.X.; Zhuang, Z.Y.; Woolf, C.J.; Ji, R.R. p38 mitogen-activated protein kinase is activated after a spinal
nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of
neuropathic pain. J. Neurosci. 2003,23, 4017–4022. [CrossRef] [PubMed]
194.
Zhuang, Z.Y.; Gerner, P.; Woolf, C.J.; Ji, R.R. ERK is sequentially activated in neurons, microglia, and astrocytes
by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain
2005
,
114, 149–159. [CrossRef]
195.
Romero-Sandoval, E.A.; Horvath, R.J.; DeLeo, J.A. Neuroimmune interactions and pain: Focus onglial-modulating
targets. Curr. Opin. Investig. Drugs 2008,9, 726–734.
196. Unruh, A.M. Gender variations in clinical pain experience. Pain 1996,65, 123–167. [CrossRef]
197.
Fillingim, R.B.; Gear, R.W. Sex differences in opioid analgesia: Clinical and experimental findings. Eur. J. Pain
2004,8, 413–425. [CrossRef]
198.
Abraham, A.; Barnett, C.; Katzberg, H.D.; Lovblom, L.E.; Perkins, B.A.; Bril, V. Sex differences in neuropathic
pain intensity in diabetes. J. Neurol. Sci. 2018,388, 103–106. [CrossRef]
199.
Cardinez, N.; Lovblom, L.E.; Bai, J.W.; Lewis, E.; Abraham, A.; Scarr, D.; Lovshin, J.A.; Lytvyn, Y.; Boulet, G.;
Farooqi, M.A.; et al. Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian
Study of Longevity in Type 1 Diabetes. J. Diabetes Complicat. 2018,32, 660–664. [CrossRef]
200.
Cardinez, N.; Lovblom, L.E.; Orszag, A.; Bril, V.; Cherney, D.Z.; Perkins, B.A. Sex differences in neuropathy
& neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes.
J. Diabetes Complicat. 2019,33, 107397. [CrossRef]
201.
Naji-Esfahani, H.; Vaseghi, G.; Safaeian, L.; Pilehvarian, A.A.; Abed, A.; Rafieian-Kopaei, M. Gender differences
in a mouse model of chemotherapy-induced neuropathic pain. Lab. Anim.
2016
,50, 15–20. [CrossRef]
[PubMed]
202.
Guindon, J.; Blanton, H.; Brauman, S.; Donckels, K.; Narasimhan, M.; Benamar, K. Sex Differences in a
Rodent Model of HIV-1-Associated Neuropathic Pain. Int. J. Mol. Sci. 2019,20, 1196. [CrossRef] [PubMed]
203.
Vacca, V.; Marinelli, S.; Pieroni, L.; Urbani, A.; Luvisetto, S.; Pavone, F. 17beta-estradiol counteracts neuropathic
pain: A behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice.
Sci. Rep. 2016,6, 18980. [CrossRef] [PubMed]
204.
Aloisi, A.M. Gonadal hormones and sex differences in pain reactivity. Clin. J. Pain
2003
,19, 168–174.
[CrossRef]
205.
Craft, R.M.; Mogil, J.S.; Aloisi, A.M. Sex differences in pain and analgesia: The role of gonadal hormones.
Eur. J. Pain 2004,8, 397–411. [CrossRef]
206.
Ceccarelli, I.; Scaramuzzino, A.; Massafra, C.; Aloisi, A.M. The behavioral and neuronal effects induced
by repetitive nociceptive stimulation are affected by gonadal hormones in male rats. Pain
2003
,104, 35–47.
[CrossRef]
207.
Aloisi, A.M.; Bonifazi, M. Sex hormones, central nervous system and pain. Horm. Behav.
2006
,50, 1–7.
[CrossRef]
208.
Hau, M.; Dominguez, O.A.; Evrard, H.C. Testosterone reduces responsiveness to nociceptive stimuli in a
wild bird. Horm. Behav. 2004,46, 165–170. [CrossRef]
Int. J. Mol. Sci. 2020,21, 9000 25 of 25
209.
Gaumond, I.; Arsenault, P.; Marchand, S. The role of sex hormones on formalin-induced nociceptive responses.
Brain Res. 2002,958, 139–145. [CrossRef]
210.
Gaumond, I.; Arsenault, P.; Marchand, S. Specificity of female and male sex hormones on excitatory and
inhibitory phases of formalin-induced nociceptive responses. Brain Res. 2005,1052, 105–111. [CrossRef]
211.
Wang, Y.C.; Li, N.; Zhao, Y.; Zhang, L.J. Effects of female sex hormones on chemotherapeutic paclitaxel-induced
neuropathic pain and involvement of inflammatory signal. J. Biol. Regul. Homeost. Agents
2018
,32, 1157–1163.
212.
Lee, J.Y.; Choi, H.Y.; Ju, B.G.; Yune, T.Y. Estrogen alleviates neuropathic pain induced after spinal cord injury
by inhibiting microglia and astrocyte activation. Biochim. Biophys. Acta Mol. Basis Dis.
2018
,1864, 2472–2480.
[CrossRef] [PubMed]
213.
Piu, F.; Cheevers, C.; Hyldtoft, L.; Gardell, L.R.; Del Tredici, A.L.; Andersen, C.B.; Fairbairn, L.C.; Lund, B.W.;
Gustafsson, M.; Schiffer, H.H.; et al. Broad modulation of neuropathic pain states by a selective estrogen
receptor beta agonist. Eur. J. Pharmacol. 2008,590, 423–429. [CrossRef] [PubMed]
214.
Ma, J.N.; McFarland, K.; Olsson, R.; Burstein, E.S. Estrogen Receptor Beta Selective Agonists as Agents to
Treat Chemotherapeutic-Induced Neuropathic Pain. ACS Chem. Neurosci.
2016
,7, 1180–1187. [CrossRef]
[PubMed]
Publisher’s Note:
MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
